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Development and implementation of a dynamic heterogeneous proton equivalent 
anthropomorphic thorax phantom for the assessment of scanned proton beam 
therapy 
By: James Leroy Neihart, B.S. 
Chair of Advisory Committee: David Followill, Ph.D 
Proton therapy has been gaining ground recently in radiation oncology.  To date, the most 
successful utilization of proton therapy is in head and neck cases as well as prostate cases.  
These tumor locations do not suffer from the resulting difficulties of treatment delivery as a 
result of respiratory motion.  Lung tumors require either breath hold or motion tracking, neither 
of which have been assessed with an end-to-end phantom for proton treatments.  Currently, the 
RPC does not have a dynamic thoracic phantom for proton therapy procedure assessment.  
Additionally, such a phantom could be an excellent means of assessing quality assurance of the 
procedures of proton therapy centers wishing to participate in clinical trials.  An eventual goal 
of this phantom is to have a means of evaluating and auditing institutions for the ability to start 
clinical trials utilizing proton therapy procedures for lung cancers.  Therefore, the hypothesis of 
this study is that a dynamic anthropomorphic thoracic phantom can be created to evaluate end-
to-end proton therapy treatment procedures for lung cancer to assure agreement between the 
measured and calculated dose within 5% / 5 mm with a reproducibility of 2%.  Multiple 
materials were assessed for thoracic heterogeneity equivalency.  The phantom was designed 
from the materials found to be in greatest agreement.  The phantom was treated in an end-to-end 
treatment four times, which included simulation, treatment planning and treatment delivery.  
Each treatment plan was delivered three times to assess reproducibility.  The dose measured 
within the phantom was compared to that of the treatment plan.  The hypothesis was fully 
supported for three of the treatment plans, but failed the reproducibility requirement for the 
most aggressive treatment plan.       
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1 Introduction and Background 
1.1 Statement of Problem 
1.1.1 General Problem 
Until recently proton therapy has been limited to research institutions or physics 
departments because of the immense size and cost of proton therapy facilities.  Each 
system was created as a one-of-a-kind.  Currently, proton therapy is in a state of rapid 
expansion and implementation at large medical institutions as well as smaller stand-
alone facilities.  Proton accelerators have recently been designed to fit within a single 
linear accelerator vault [1], which allows radiation oncology departments to add proton 
therapy to their practice in a retrofitted treatment vault.  Because proton accelerators 
come in many sizes, beam line configurations, and particle acceleration methods 
radiation quality assurance (QA) measurements must be made before all proton beams 
can be assumed to deliver comparable doses to clinical targets.  Since the number of 
proton therapy sites and clinical trials that employ proton therapy are increasing, an 
effort to establish dose delivery consistency must be in place to assure that multi-
institution clinical studies are valid.  Worldwide there are 37 proton centers currently 
operational [2].  An additional twenty-four institutions worldwide are also in the 
process of constructing or developing proton facilities, many of which are single gantry 
systems [3]. 
The Radiological Physics Center (RPC) was established in 1968 to assure the 
NCI and Cooperative Study Groups that institutions participating in clinical trials 
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delivered clinically comparable and consistent radiation doses [4].  One of the most 
efficient means of assuring a participating institution’s beam delivery is to mail a 
phantom fitted with dosimeters and have them irradiate it following a treatment plan in 
an end-to-end QA test.  Such a QA system saves time for the RPC and creates a 
standard irradiation condition for various participating institutions.  The RPC has 
experience with numerous phantom and dosimeter configurations optimized for linear 
accelerator, brachytherapy and proton treatment applications [4] [5] [6]. 
1.1.2 Specific Problem 
Current thoracic phantoms used by the RPC are designed specifically for use in 
photon beams.  However, materials and plastics used in these phantoms do not 
correspond to tissue equivalent materials when placed in a proton beam instead of a 
photon beam as the phantoms were originally designed.  The goal of this research is to 
develop and commission a phantom which will serve to assess the ability of a proton 
facility to deliver a planned dose to a target within a lung heterogeneity influenced by 
respiratory motion without having to manually override material properties in the 
treatment planning system.  The phantom will be composed of tissue simulating 
materials, which in the thorax includes materials that have vastly different proton 
stopping power ratios.  The phantom is intended to be easily mailed to institutions 
intending to participate in current or future clinical trials pertaining to proton therapy of 
lung cancer. 
1.1.3 Importance of Topic 
While the theoretical advantages of proton therapy are numerous, and are 
discussed in detail in sections 1.5.1 and 1.5.10, proton therapy treatments still require 
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clinical trials to prove efficacy, although some in the field debate this [7].  Clinical trials 
are an essential aspect of scientific advancement in the medical community.  Proton 
therapy clinical trials are currently needed to determine the efficacy of treating with 
protons as opposed to the current standard of care photon treatments.  Current and 
proposed proton trials are made more difficult by the fact that each proton therapy 
center worldwide is designed and built differently.  With a large variation in the beam 
delivery and treatment parameters available at different proton centers, the need for an 
end-to-end quality assurance tool becomes imperative to assure consistency of patient 
data from different centers.  The mission of the RPC is especially important in the case 
of proton therapy, where there is less uniformity of beam delivery systems than in linear 
accelerator photon delivery.  Inconsistencies and incomparable delivered doses reduce 
the efficacy of clinical trials and can compromise validity of conclusions, thus they 
must be minimized systematically as much as possible.  The use of a well-designed 
anthropomorphic QA phantom helps to ensure that the treatment delivered across 
participating institutions is comparable. 
Lung and bronchus cancer has the second highest estimated age-adjusted 
incidence rates for men and women in 2012 within the United States, but is the leading 
cancer in estimated age-adjusted mortality rates for the same cohort [8].  Although the 
mortality rate for men has been decreasing since the mid-1990s, lung cancer remains the 
highest cancer in mortality rate for the US population.  Local tumor control has 
commonly been to blame for the high mortality associated with lung cancer.  Proton 
therapy exhibits the potential for higher dose escalation than achievable by IMRT or 
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other photon beam techniques, which may increase local control in patients without 
compromising dose to surrounding critical structures. 
1.2 Hypothesis 
A dynamic heterogeneous anthropomorphic thorax phantom can be designed and 
built to evaluate the end-to-end proton therapy treatment procedures for lung cancer to 
assure agreement between the measured and calculated dose within ±5%/5 mm with a 
reproducibility of ±2%. 
Specific Aims: 
1. Determine tissue equivalent materials for protons for soft tissue, lung and bone. 
2. Design and build a lung anthropomorphic QA phantom for proton therapy using 
the identified tissue equivalent materials.   
3. Image the dynamic phantom with 4D CT and develop a clinically applicable 
treatment plan for scattered and spot scanned proton beams. 
4. Irradiate the phantom according to the treatment plans with point and planar 
dosimeters to generate measured dose distribution. 
5. Compare the measured and planned dose distributions and determine accuracy 
and precision. 
1.3 Research Approach 
Methodology: 
1. Tissue equivalency will be determined by measured proton stopping powers and 
HUs corresponding to anatomical data. 
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2. The phantom will be designed with lung tissue, soft tissues, and bone simulating 
materials in an anthropomorphic and clinically relevant size and geometry. 
3. The phantom will be imaged with a 4DCT scanner to utilize the time varying 
capabilities of the imaging modality.  The image will be used to develop 
treatment plans (scattered and scanned beams) using Eclipse proton planning 
system and will be generated based on typical clinical constraints and practices 
used by PTC-H dosimetry for lung cancer.  
4. The phantom will accommodate TLD capsules and radiochromic film for 
dosimetry measurement.  The phantom will be irradiated according to the 
treatment plan at least three separate times for each plan. 
5. The measured dose distributions and point doses will be compared to the 
calculated planned distributions and point doses using a gamma analysis will be 
used to determine agreement and reproducibility. 
1.4 Limitations 
1.4.1 Limitations of the Phantom 
The design of the phantom must make assumptions as well as neglect certain 
aspects of a human thorax during irradiation.  Fundamentally in design, the phantom 
cannot simulate all types of tumor motion.  Shirato et. al have shown that various 3-
dimensional trajectories are possible within the lungs based on location within the 
thorax as well as other factors such as attachment to the ribs or diaphragm [9].  The 
dosimetry insert is limited in design to a single tumor location as well as a restriction on 
rotation because the sensitivity to setup error of the orthogonal films [10].  Additionally, 
the motion insert as well as the static portion of the phantom restrict the possibility of 
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deformable anatomy during the breathing cycle.  For more information on deformable 
inserts or higher degrees of motion including rotation, the reader is referred to studies 
[11] and [12] respectively. 
The simulated breathing pattern is also subject to limitations that differ from 
clinical possibilities.  The breathing patterns used must assume amplitude as well as 
periodic function.  Others have shown that a simple sinusoidal breathing pattern may 
not accurately simulate interplay effects [13].  Summarized by the AAPM Report No. 
91, the amplitude of lung tumor motion can vary widely, thus any single choice in 
amplitude will result in limited clinical applicability.  However, the amplitude of tumor 
motion for a single patient during 4D simulation as well as treatment may in fact be 
accurately simulated by a single choice in amplitude for tumor motion [14]. 
1.4.2 Limitations of the Proton Beam Delivery System 
The beam delivery system used for this study was the synchrotron accelerator at 
the PTC-H at MD Anderson Cancer Center.  Synchrotron based spot scanning has 
limitations due to the time it takes for the beam to change energy, which have been 
studied by others, [15] and is discussed in section 1.5.3.2.  Specifically, if the 
respiratory cycle is close to the energy change time, the interplay effect may result in 
unacceptable dose deliveries [13]. 
The spot size at the PTC-H at MD Anderson Cancer Center also presents a 
limitation on the dose conformity delivered to the relatively small tumor volume.  The 
spot size of the scanning beam at the Proton Therapy Center at MD Anderson Cancer 
Center is approximately 5 mm at 250 MeV and 10 mm at 70 MeV with the use of an 
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energy absorber [16].  Thus, smaller tumor diameters may receive insufficient delivered 
dose due to the large spot size. 
1.5 Literature Review 
1.5.1 Protons in Therapy 
Proton beams for therapy have a number of advantages over photons.  These 
advantages arise because of the physical differences of the proton as compared to the 
photon and the manner in which the proton deposits energy as it passes through matter. 
The most obvious advantage of protons in radiation therapy is the high 
ionization density near the end of the range of the proton [17].  This property of protons 
as they slow down in a medium allows the maximum energy deposition to be chosen as 
opposed to the predetermined depth of maximum dose as in photon therapy treatments 
[18].  Figure 1.1 demonstrates the dose deposition as a function of depth in water of a 
monoenergetic proton beam. 
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Figure 1.1:  Depth dose curve of a "pristine" proton beam 
Because the proton is a charged particle, it exhibits a finite range that is a 
function of its kinetic energy.  This property is advantageous because healthy tissue 
distal to the target can be spared with minimal doses. 
Clinically, a monoenergetic proton beam is not used because solid tumors have 
non-zero depth.  The use of either range modulators, ridge filters or the superposition of 
many monoenergetic beams produces a spread out Bragg peak (SOBP), shown in 
Figure 1.2.  The plateau of the SOBP can be further extended by the addition of lower 
energy pristine Bragg peaks; doing so will also increase the relative dose at the entrance 
of the tissue. 
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Figure 1.2:  Formation of an SOBP from multiple pristine Bragg peaks 
Proton therapy results in a lower integral dose than traditional photon treatments 
[19].  This property is a strong rationale for the utilization of proton therapy in the 
treatment of pediatric malignancies such as medulloblastoma where the effect of a low 
integral dose is easily noticeable when comparing treatment plans.  A lower integral 
dose is associated with a lower rate of second malignancies as a result of the treatment.  
In the specific case of lung cancer, the lower integral dose from proton therapy reduces 
the lung, heart and spinal cord dose volume histograms (DVHs), which may be dose- 
limiting to the target in photon therapy techniques. 
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The lateral penumbra of a proton beam is generally much sharper than that of a 
photon beam with the exception of high energy photon beams at depths greater than 
approximately 22 cm in water [20].  The lateral penumbra of a proton beam increases as 
the protons travel through air, the patient, or other materials in the beam path.  
Maintaining a small penumbra is clinically desirable because it creates greater dose 
falloff outside the tumor volume.  Without accurate end-to-end positional 
reproducibility, a beam with a small penumbra has the potential to underdose the target 
or deliver high dose to normal tissue.  A treatment plan utilizing high dose gradients 
near target borders or critical organs may yield exceptional DVH characteristics, but 
upon treatment delivery, may yield undesirable dose delivery. 
1.5.2 Radiobiology of Proton Therapy 
Heavy charged particles demonstrate radiobiologic advantages over X-rays.  
These advantages include improved relative biological effectiveness (RBE) and oxygen 
enhancement ratio (OER).  In a highly conformal therapy, an improved RBE is one that 
is increased above unity.  Conversely, an improved OER is one that approaches unity.  
The equations for RBE and OER are shown below in Equation 1 and Equation 2 
respectively, and in both equations the doses are for the same biological effect. 
 
    
                            (              )
                      
 
Equation 1 
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Equation 2 
 
 
Current clinical proton doses are modified by a RBE of 1.1.  This means that 
protons yield the same biological endpoint as photons at a physical dose 10% lower 
than photons.  The clinical use of this constant RBE value was based on in vitro and in 
vivo studies of murine tumors [21].  The proton therapy research community generally 
recognizes that proton RBE is a function of linear energy transfer (LET), and dose, but 
both relationships are still under investigation [22].  While the constant value of RBE 
may not be correct, it provides a good average and is easily implemented in a clinical 
setting.  Uncertainty in the biological effects of proton therapy translates to an 
uncertainty in appropriate tumor doses as well as critical structure limitations.  In the 
future, proton therapy treatment planning systems may be able to optimize biological 
effective dose distributions. 
In regions of hypoxia, the OER is an important metric of treatment 
effectiveness.  As the LET of a particle increases at the end of its pathlength, the OER 
decreases [23].  At an LET of approximately 200 keV/µm, the OER of a cell line 
approaches unity, meaning the increased cellular damage of a high LET particle is equal 
in effectiveness to the decrease in cellular damage due to the hypoxic environment [24].  
However, this enhancement is smaller in clinical proton beams where the maximum 
LET in the distal falloff region of the Bragg peak is on the order of 10 keV/µm [22].  
Additionally to tumor hypoxia, normal tissue distal to the tumor may be enhanced by 
the OER because of the high LET distal to the target. 
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1.5.3 Proton Accelerators 
1.5.3.1 Cyclotron 
Cyclotron accelerators produce monoenergetic protons and are also called 
isochronous cyclotrons.  The energy for proton therapy is typically 250 MeV to 
accommodate the highest practical energy needed for treatment procedures, but this 
may vary between proton center, proton machines or treatment applications.  Desired 
clinical energies lower than the maximum accelerated value are achieved by the use of 
energy degraders [25].  
The most significant advantage of proton cyclotron accelerators is that they 
produce a constant beam current [25].  This allows the beam intensity to be adjusted 
rapidly.  In the case of a moving lung tumor, future advances may allow for real-time 
tracking where the proton beam energy would rapidly modulate to accommodate tumor 
motion.  However, with the use of energy degraders, the beam divergence may increase 
without additional downstream focusing magnets.  A disadvantage of cyclotrons is that 
there is a potential for significant beam loss within the accelerator, which results in 
machine hardware becoming radioactive [25].  This is also true of any additional 
hardware put in the beam path. 
1.5.3.2 Synchrotron 
Synchrotrons have the ability to accelerate protons to a range of different 
energies.  The PTC-H, for example, has the ability to accelerate protons to 94 discrete 
energies from 72.5 – 250 MeV without the use of an energy degrader [16].  Energy 
modulation however, is not rapid because the beam is extracted in pulses, or “spills”.  
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The common energy change rates for synchrotrons are between 0.5 and 5 seconds [25].  
Faster energy selection can be accomplished by the use of a range modulator wheel in 
the beam line, however; range modulator wheels are only used for passive scattered 
beam delivery and they produce a specific SOBP for use with a single accelerated 
proton energy. 
1.5.4 Proton Beam Delivery Methods 
1.5.4.1 Passive Scattered Beams 
The most straightforward method of delivering a charged particle beam is by the 
passive scattered method.  Passive scatter beam modifying components include range 
modulators, apertures and range compensators.  A monoenergetic proton beam, with a 
pristine Bragg peak has too sharp of a peak to cover clinically relevant treatment 
volumes [18].  Therefore, a means of changing the energy of the proton beam is needed 
to cover the treatment volume in the depth dimension.  In passive scattering, this is done 
by using of a range modulator. 
Neutron dose in the passively scattered proton beam is higher than that of the 
spot scanned proton beam.  Neutron dose generated from within the patient by the 
protons undergoing nuclear interactions is unavoidable regardless of the delivery 
method.  Neutron dose from the nuclear interactions within the scattering system in the 
beam gantry, however, is minimized in the spot scanned system.  In passive scattered 
beams, this external neutron dose can be minimized by increasing the proton utilization 
efficiency [26].  Practically, this can be achieved by selecting the smallest achievable 
beam size for a given aperture. 
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As its name implies, passive scattering ultimately is a passive beam delivery 
method, thus for a dynamic system such as a lung tumor located in healthy aerated lung 
tissue, the passive scatter technique is inherently suboptimal without further advanced 
techniques. 
1.5.4.2 Spot Scanned Beams 
Due to the electromagnetic charge of the proton, a thin beam of protons can be 
steered by the use of magnets [26].  Two common names for this delivery method are 
spot scanning and pencil beam scanning.  Scanned beams are dynamically modified 
before entering the patient, therefore they do not require any patient specific hardware 
such as collimators or compensators [18]. 
As mentioned in section 1.5.4.1, the secondary neutron dose is lower in a 
scanned system than a passively delivered beam.  The secondary neutron dose is 
unwanted and not accounted for in treatment planning or tolerance limits of critical 
structures. 
A major advantage spot scanned proton beams have over passively delivered 
beams is the ability to generate intensity modulated proton therapy (IMPT) treatment 
plans.  Intensity modulation has shown to be a successful technical progression in 
photon therapy, and has given clinical staff the ability to inverse plan a treatment.  In 
the same way, intensity modulation for proton therapy seems to be a logical step from 
forward planned treatments.  Each individual scanned pencil beam has the ability to be 
optimized to create a homogeneous dose distribution within the target volume over a 
sufficient number of fields [26]. 
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1.5.5 Range Uncertainties in Proton Therapy 
One of the attractive properties of proton therapy is the rapid energy deposition 
at the end of the range of the proton beam.  Additionally, distal to the high dose 
gradient, there is very little dose deposited.  The possibility for tissue sparing distal to 
the target volume is a key advantage of proton therapy over conventional photon 
therapy.  However, this dose distribution of the proton also has its disadvantages. 
Errors resulting in range uncertainties are exacerbated in proton therapy where 
the energy deposition of the proton is highly concentrated at the end of its range.  This 
phenomenon makes proton beam delivery much more sensitive to tissue 
inhomogeneities than photon beam dose deliveries [1].  This effect is shown in Figure 
1.3.  The photon beam is relatively unaffected by 1 mm of additional water equivalent 
thickness (WET) of material, while the coverage of the SOBP is noticeably shifted, 
however the maximum relative dose within the target is unchanged.  An additional 
difficulty in proton beam delivery is that when these tissue inhomogeneity range 
uncertainties occur, the target can receive a severe under-dose, and surrounding healthy 
tissue can receive unintended maximum dose levels. 
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Figure 1.3:  Illustration of the effects of an additional millimeter of WET in an 
SOBP and 6 MV beam 
In the case of lung cancer, the tumor with density properties similar to water is 
located within or adjacent to aerated low density lung tissue.  This presents a different 
dosimetric situation than tumors located in more uniform tissue such as the brain or 
prostate.  The stopping power of lung tissue is approximately three times lower than 
that of soft tissue, thus the proton beam travels further in lung tissue.  Uncertainty in the 
range results in an exacerbated effect in lung tissue, as the high dose deposited by the 
proton beam travels farther in lung tissue than in soft tissue distal to the target [26].  
Additionally, the range adjustment step becomes approximately three times larger 
spatially between layers of dose that can be delivered in lung tissue compared to soft 
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tissue for spot scanned beam delivery.  The density variation along a path from the skin 
to a lung tumor presents an added complexity to proton therapy delivery. 
Range and dose uncertainties are also introduced by the calibration of 
Hounsfield units (HU) to relative stopping power (RLSP).  Because the interactions of 
photons and protons differ in matter, a calibration curve is necessary to plan a proton 
therapy treatment on a CT image set.  Using stoichiometric and empirical data, a 
calibration curves has been generated from animal tissues to show a bilinear calibration 
curve relating HU to RLSP [27].  Experimental verification has shown that the total 
uncertainty in the soft tissue portion of the calibration curve is ±1.1% while the high 
HU portion of the calibration curve associated with bone is ±1.8% [28].       
1.5.6 Intrafractional Motion of Lung Tumors 
In addition to the differences in densities ranging from bone to lung tissue that 
the proton beam may traverse, delivering a charged particle beam to tumors located in 
the lung is also complicated by respiratory motion.  Tumor motion is typically primarily 
in the superioinferior direction [26].  Typical techniques that are used for both photon 
and proton therapy respiratory motion mitigation are discussed in section 1.5.8. 
Intrafractional motion results in potential errors in radiation dose delivery when 
the motion is severe and motion mitigation techniques are either not used or under-
utilized.  The consequences of both interfractional and intrafractional motion include 
unintentional target misses, reduced target coverage and elevated normal tissue dose.  
Due to the plan uncertainty, the intrafractional tumor motion is accounted for by 4DCT 
plans for patients [29]. 
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Real time tumor motion has been tracked by diagnostic fluoroscopy with the use 
of gold markers, which were inserted into the tumor [9] [30].  Of the studies 
summarized in the AAPM Report No. 91, the range of motion in the SI direction alone 
was 0 – 34 mm [14].  These studies and others have provided lung tumor motion data 
for many patients but have no common trajectory.  Research has also shown that lung 
tumor motion is independent of tumor size, location within the lung, or extent of 
pulmonary function [31].  Therefore, modern radiotherapy treatment of lung cancer 
requires a 4DCT scan to assess the magnitude and direction of each patient’s motion 
because there is not an a priori motion pattern. 
1.5.7 Imaging Acquisitions for Thoracic Tumors in Proton Therapy 
Because respiratory motion is the most severe intrafractional motion in the 
human body, time resolved imaging techniques can serve to better define the ITV of the 
lung tumor.  Others have shown that 3-dimensional imaging is inadequate for proton 
treatment planning of lung tumors [32].  4DCT scans effectively result in a 3-
dimensional imaging set for each of the binned respiratory phases.  Treatment planning 
in proton therapy utilizes the HU recorded by the CT scanner to calculate the relative 
stopping power of each pixel. 
The binning of respiratory phases is done by the use of a motion monitoring 
device.  Examples of clinical devices used are spirometers, which measure airflow, 
strain gauges, which measure abdominal circumference, and fiducials tracked by rigid 
cameras, which measure one dimensional movement of the chest [33].  These devices 
provide reproducible measurements which act as a surrogate for tumor motion. 
19 
 
Many clinics and researchers use a commercial fiducial and camera system 
called Real-time Position Management™ (RPM) (Varian Medical Systems, Palo Alto, 
CA).  This device uses a rigidly fixed CCD camera located at the inferior end of the 
imaging or treatment couch and a box containing two or six reflective fiducial markers.  
The rigid camera also contains an infrared light.  The emitted infrared light reflects off 
of the fiducial reflectors and is detected by the CCD camera.  An image of the rigid 
infrared light and camera system is shown in Figure 1.4 below. 
 
Figure 1.4:  The RPM infrared camera system used in free breathing and breath 
hold simulations and treatments 
The acquisition of both the CT slice and the respiratory phase is used to 
construct a phase dependent image set.  At MD Anderson Cancer Center, the respiratory 
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cycle is divided into 10 phases for 4DCT acquisitions.  The information gained from a 
4DCT acquisition includes range and direction of tumor motion in 3-dimensions, 
motion of critical organs, and a baseline breathing pattern of the patient to identify 
irregular breathing amplitudes during treatment.  Although 4DCT generates phase 
dependent imaging, motion still exists in between the phase bins.  This uncertainty 
however is much smaller than that of a single 3D imaging acquisition and has been 
measured to blur an object by up to 8% of its length due to interphase motion and the 
interplay effect [34].  The 4DCT image set is used for treatment planning and is also 
used to better facilitate additional motion mitigation techniques mentioned in the 
following section. 
1.5.8 Motion Mitigation Techniques 
Currently motion mitigation techniques include rescanning, beam gating, and 
beam tracking [35].  These motion management techniques are listed in order of 
conformality as well as sophistication in delivery.  Many of the motion mitigation 
techniques for proton therapy can benefit from the efforts made on conventional photon 
therapy respiratory motion mitigation. 
Rescanning is simply taking advantage of the law of averages.  If the treatment 
includes many fractions, an area of over dose in one fraction may be an area of under 
dose in another fraction.  With regards to the interplay effect, fractionation was found to 
reduce dose deviations up to 33% from a single fraction beam delivery [36].  This 
principal can also be further applied when each fraction includes many irradiations of 
each spot separated in time to achieve the desired dose in that fraction.  Currently 
different rescanning techniques are being investigated, such as volumetric [36], and 
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patient specific optimization [37].  However, until more advanced techniques are 
validated clinically, rescanning does not offer optimization and should only be used 
when no other motion mitigation technique can be used effectively. 
Beam gating is a motion mitigation technique that limits beam on time to phases 
of the respiratory cycle where the tumor is located in the beam path.  As the tumor 
moves out of the beam path, the beam turns off until the tumor reenters the beam path.  
The target, however, still moves during each phase.  Therefore the motion mitigation 
achieved by beam gating is only by reducing the motion within the beam-on time, not 
eliminating the effect of target motion [35].  Additionally, gating in this manner also 
makes the assumption that the tumor motion during simulation is identical to that during 
the time of treatment. 
Respiratory motion can be reduced by breathing techniques.  Shallow breathing, 
for example, results in a reduced tumor amplitude during the breathing cycle.  Even 
more so, breath-hold techniques can potentially freeze the respiratory motion while the 
beam is on.  The most important aspect of these breathing techniques is the 
reproducibility of the breathing pattern.  Experimental measurements using a 
spirometer-based monitoring system yielded an average reproducibility in the tumor 
position of approximately 3 mm in patients [38].  Beam gating under breath hold 
conditions provides a powerful motion mitigation technique used in both photon and 
proton therapy. 
The most complex of the motion mitigation techniques is beam tracking.  Beam 
tracking is the continuous repositioning of the beam path and energy based on image 
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guided tumor position or other tumor motion surrogates.  Beam tracking can only be 
used in spot scanning beam delivery, because of the active beam steering and range 
modulation required.  This technique requires patient monitoring as well as a proton 
accelerator capable of changing beam energy rapidly.   Beam tracking has the potential 
to be the most conformal motion mitigation technique, but at the cost of high technical 
complexity [35]. 
1.5.9 Thoracic Phantoms in Proton Therapy 
Dynamic and static phantoms have been used in photon therapy to good success.  
Commercial systems include motion inserts which can accommodate imaging, and 
multiple types of dosimeters.  Tissue equivalent materials in photon beams are used to 
simulate tissue heterogeneities. 
The materials which are tissue equivalent in photon beams are not necessarily 
tissue equivalent in proton beams.  Because of this, thoracic phantoms used in proton 
beams should be made of materials that simulate tissue accurately within a proton beam 
otherwise the materials must have their properties, such as HU or RLSP, manually 
changed within the treatment planning software.  The latter strategy has been used by 
others because of the commercially available materials and phantoms.  An example is a 
PVC artificial skeleton used with a robotic arm to move a detector bank with 6-
dimensional motion [12].  This configuration is quite complex, however PVC does not 
simulate tissue adequately enough to avoid manual override of the HU of the ribs.  The 
RPC measured a 12% underresponse of PVC RLSP with respect to the Eclipse 
calculated RLSP. 
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1.5.10 Current State of Proton Therapy in Lung Cancer 
Currently, proton therapy is used to treat thoracic cancers at many institutions in 
the United States.  Of the institutions monitored by the RPC, each uses a unique 
combination of motion management techniques, immobilization devices, lateral margins 
and setup tolerances.  The potential benefits of proton therapy over photon therapy for 
thoracic tumors include: smaller beam penumbrae, finite range of protons, and dose 
escalation due to normal tissue sparing [32]. 
The potential for dose escalation is an important feature of the use of proton 
therapy in thoracic cancers.  Local control in lung cancer patients with total doses up to 
65 Gy under standard fractionation in photon radiation therapy was found to be less 
than 20% [39].  A clinical trial of photon therapy dose escalation for NSCLC 
demonstrated that a total dose of approximately 84 Gy resulted in a TCP of 50% as 
compared to a TCP of approximately 25% at 70 Gy [40].  The results of this study 
showed a sigmoid-shaped dose response curve.  However, the common limiting factor 
to dose escalation in photon therapy is the unacceptable dose to normal tissue or critical 
organs.  Because protons stop with a finite range, many in the radiation oncology field 
see a benefit from protons in achieving high dose in the tumor volume while also 
maintaining tolerable doses to normal and critical tissue. 
1.5.10.1 Critical Organ Threshold Doses 
Critical structures in the thorax include the contralateral lung, heart and spinal cord.  
The dose these critical structures receive during treatment depends on the tumor 
location, motion and size.  Spinal cord, total lung, and heart dose-volume constraints 
used at MD Anderson Cancer Center for definitive radiation therapy in thoracic 
24 
 
treatments are shown in Table 1.1  [39].  The spinal cord is a serial organ, meaning that 
the maximum dose determines the likelihood of complication, which in the case of the 
spinal cord, is paralysis.   Other organs in the thorax exhibit a parallel structure for 
radiation damage.  Patients irradiated above a high maximum dose over a small lung 
volume or irradiated above a relatively low maximum dose over a large lung volume 
have an increased risk of severe pneumonitis.  Radiation-induced cardiac side-effects 
have been of concern in the treatment of thoracic malignancies as well as breast 
irradiations.  The heart exhibits both limitations on maximum tolerable total volume 
dose as well as a secondary dose-volume constraint shown below. 
Organ Dose Volume 
Spinal cord 50 Gy - 
Lung 20 Gy <40% 
Heart 40 Gy 
50 Gy 
<100% 
<50% 
Table 1.1:  Dose-volume constraints for three common critical structures in 
thoracic radiotherapy treatments 
2 Materials and Methods 
2.1 Phantom Design 
2.1.1 Phantom Design Considerations 
Due to the high sensitivity of range uncertainties in proton therapy, the phantom 
should be designed in such a way as to minimize unnecessary air gaps, material 
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interfaces and materials of unacceptably different stopping powers than those of 
anatomical equivalents.  In order to properly account for the clinically applicable 
anatomical heterogeneities, the phantom should include heterogeneities in the beam 
path such as bone and lung.  The design should include a section of lung that is able to 
move freely by an actuator with high reproducibility. 
The dosimetry insert should be able to accommodate absolute point dose 
dosimeters such as TLD.  Additionally, the insert should be able to accommodate 
radiochromic films to measure dose distributions within the phantom.  The dosimetry 
measurements provided by the films can be normalized by the absolute point dose from 
the TLD, which corresponds to a designated point in the film plane [41]. 
A proton dosimetry insert previously designed by Blatnica was used in the 
design of this phantom.  The insert was designed to minimize the air gaps present in 
previous photon dosimetry inserts which were not as sensitive to air gaps in comparing 
the planned and measured dose distributions.  The design considerations of the insert 
included choosing proton-appropriate materials, maintaining proper film orientation, 
and minimizing air gaps [6].  An image of the insert is shown in Figure 2.1. 
The insert is composed of balsa wood and is covered by a thin high impact 
polystyrene cylinder.  Within the center of the insert is a high impact polystyrene 
ellipsoid which is the clinical target and simulates the gross tumor volume. 
The design should also include a heart structure which can accommodate film.  
This addition of an avoidance structure with planar dosimetry allows for out of field or 
distal dose measurements. 
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Due to the dose distributions in proton therapy, a phantom with a single lung will 
provide a sufficient simulation of a typical anatomical proton therapy case.  Others have 
shown that the contralateral lung V5, even with dose escalation, is lower in proton 
therapy than IMRT plans at conventional doses [42].  Therefore, the ipsilateral lung is 
the only lung necessary; the contralateral lung will receive negligible dose because the 
low dose distribution distal to the target volume.  Considering the low distal dose, the 
spinal section was also omitted from the phantom design.  Conventional proton therapy 
beam angles for thoracic cases never enter through the contralateral lung.  Due to the 
limited treatment angles that the phantom accommodates, this decision is justifiable 
without noticeable effect on the dose delivered to the target.  Future studies with this 
phantom may incorporate dosimeters at the location of the spinal cord simply by the 
addition of a cord material capable of accommodating dosimeters.  The clinically 
relevant toxicity for the spinal cord is a maximum dose of 50 Gy [42].  Under the 
current design with a tumor located central within the left lung, it is unlikely that a 
proton therapy institution would deliver a dose of 50 Gy to the spinal cord. 
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Figure 2.1: The assembled dosimetry insert used within the phantom (left) and a 
view of the target within the balsa wedges (right) 
The initial intended motion of the tumor is approximately 2 cm in amplitude in 
the superoinferior direction and 0.7 cm in amplitude in the anteroposterior direction, but 
can be programmed to any clinically applicable amplitude.  This motion simulates a 
possible normal tumor motion pattern [9].  The phantom should be designed in such a 
way that motion tracking surrogates such as a chest displacement or abdominal 
circumference tracking systems can be used to facilitate gated treatment delivery. 
The phantom incorporates five proton equivalent material types.  These 
materials simulate lung, soft tissue, heart, tumor, and bone.  The materials chosen have 
relative stopping powers which are very close to those calculated by Eclipse Treatment 
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Planning System (TPS) at their respective Hounsfield units (HU).  The design of the 
phantom should be consistent with human anatomy as well as provide non-uniform 
linear geometry to ensure that the beam delivery is non-trivial during simulated 
treatments.  Figure 2.2 below shows the relative stopping power and HU of the tissue 
simulating materials used in the phantom compared to calculated values from the TPS. 
 
Figure 2.2: Phantom material RLSP and HU over Eclipse calculated curve 
2.1.2 Determination of Bone Equivalent Material 
An adequate proton-equivalent bone material was needed to simulate ribs within 
the phantom without having to contour them and manually adjust their HU for accurate 
calculation of proton ranges by the TPS.  In order to verify that a material is proton 
equivalent to the TPS calculated stopping power based on the material’s HU, the 
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relative stopping power must be measured.  Equation 3 below is a modified version of a 
relative stopping power equation for a test material in front of a water tank [43]. 
     
(         )
  
 Equation 3 
 
RLSP is the relative stopping power, R80,w is the distance in water to the distal 
80% ionization depth, R80,m is the distance in water beyond the test material to the distal 
80% ionization depth, tm is the thickness of the test material.  The measurements for 
relative stopping power were done using a Zebra Multi-Layer Ion Chamber (IBA, 
Schwarzenbruck, Germany).  All samples were irradiated with a 10 cm x 10 cm field 
with a SOBP of 10 cm.  Each range measurement was irradiated to 50 MU.  An image 
of the measurement setup is shown in Figure 2.3 below. 
 
Figure 2.3:  Relative stopping power measurement setup 
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A total of nine materials were tested for bone equivalency using the setup 
mentioned above.  Six of the materials were plasters or clays, two were dense woods 
and one was bone meal.  Human ribs were considered as a natural option to incorporate 
within the phantom, however, they were not used because human ribs are brittle once 
dried and develop air pockets where the spongy bone was previously contained. 
2.1.2.1 Error Analysis in RLSP and HU Measurements 
In order to test for reproducibility, error analysis was needed to determine if a 
difference in HU or RLSP was acceptable or unacceptable.  The HU measurements 
were done within Eclipse TPS and 10 HU values were taken from a line of pathlength 
through the material.  The standard deviation of the HU was reported in Figure 3.2 as 
positive and negative horizontal error bars. 
Each variable in Equation 3 above has uncertainty in its measurement.  The 
range accuracy of the distal 80% depth for water and the material is determined by the 
accuracy of the depth scanning device.  The Zebra has a range accuracy of ± 0.5 mm.  
The thickness of the machined materials was determined to also have an accuracy of ± 
0.5 mm.  The propagated fractional error in the relative stopping power is shown in 
Equation 4 below.  This uncertainty analysis was used in the generation of figures in 
section 3.2.1 and section 3.1. 
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2.2 Breathing Motion of Dosimetry Insert 
2.2.1 Insert Motion Method 
The simulated motion of the tumor was carried out by both an electromechanical 
cylinder and a lead screw based motor moving the dosimetry insert at an angle of 20º 
through the phantom.  This method may simulate clinical situations better than having 
the phantom on an oscillating motion table because the ribs, heart, and soft tissue 
surrounding the lungs do not translate during respiratory motion.  Others have 
successfully demonstrated the use of motion tables [44].  Additionally, a combination of 
motion table and electromechanical cylinder to simulate respiratory motion has also 
been studied [11]. 
The electromechanical cylinder used was the Dyadic SCN6-020-100 (Dyadic 
Systems Co., Ltd. Japan).  The cylinder is shown in Figure 2.4.  Following the 
simulations, and two irradiations the Dyadic electromechanical cylinder lost 
communication with the PC controller and was replaced with a Velmex BiSlide MN10-
0050-E01-31 (Velmex Inc., Bloomfield, NY) shown in Figure 2.5. 
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Figure 2.4:  Electromechanical cylinder used to move the dosimetry insert 
 
Figure 2.5:  Lead screw driven motor assembly used to replace the 
electromechanical cylinder 
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2.2.2 Insert Motion Types 
The electromechanical cylinder and lead screw motor are limited to 1-
dimensional motion; however, 2-dimensional motion can be simulated with the insert at 
an angle with respect to the treatment couch plane.  As mentioned in section 2.1.1, the 
initial intended motion is approximately 2 cm in amplitude along the SI direction and 7 
mm along the AP direction.  At an incline of 20º, the motion results in an amplitude of 
approximately 2.13 cm along the motion insert travel direction.  Clinically 2 cm motion 
is large for many proton facilities therefore a reduced target motion of 1.5 cm in 
amplitude was also generated for free breathing treatments. 
2.2.3 Dosimetry Insert Motion Control 
The electromechanical cylinder was controlled by software included with the 
device (PC Tool Kit, Dyadic Systems Co. Ltd., Japan).  The software allows for control 
over many parameters of the electromechanical cylinder.  The hardware allows for 256 
bytes of information to be loaded to the cylinder, which is sufficient for multiple 
simulated breathing types [11].  Additionally motion was controlled by VMX software, 
which also allows for 256 bytes of information to be stored on the controller. 
2.3 Dosimetry 
The phantom was designed to accommodate both point and planar dosimetry as 
mentioned in section 2.1.1 above. The combination of planar and point dosimetry has 
been used by the RPC for many years to good success.  The dosimetry insert 
accommodates two TLD capsules and five pieces of film to generate three planes.  
Additionally, a single piece of film was utilized at the surface of the heart. 
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2.3.1 Point Dosimetry 
The point dosimeter used in the phantom was TLD.  TLD provides an absolute 
dose measurement at the location of the dosimeter.  The RPC has extensive experience 
with TLD usage and is capable of generating reliable readings [45]. 
TLDs are passive detectors that can store integrated dose until they are read out 
with a heating cycle.  The mechanism for storing and reading dose deposited is similar 
to semiconductor detectors which exploit the presence of impurities that produce an 
electron-hole trap between the valence and conduction band of the powder [46].  Once 
the TLD is irradiated, it can be read out by heating the powder to release the electron-
hole pairs from the impurity traps, which releases thermoluminescent photons that are 
counted by a photomultiplier tube system.  In order to use TLDs for an absolute 
dosimeter, many parameters must be identified and calibrated.  This process has been 
studied by RPC to ensure reliable analysis of measurements. 
The RPC uses a LiF based TLD called TLD-100 (Harshaw Chemical Company, 
Solon, OH).  It is doped with Mg and Ti ions as the trapping and luminescence centers.  
This particular thermoluminescent material is sensitive to photons, thermal neutrons and 
charged particles [47].  The lower threshold for reliable measurements is approximately 
100 µGy [46].  The determination of delivered dose to a TLD is calculated by Equation 
5, where M is the thermoluminescent signal per unit mass of powder,     is the system 
sensitivity,    is the linearity correction factor,    is the energy correction factor, and 
   is the fading correction factor. 
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  (         )               Equation 5 
 
The fading correction factor, KF is determined at the RPC by a double 
exponential function shown in Equation 6.  Where a, b, c, d and N are batch specific 
coefficients and x is the number of days between irradiation and TLD reading.  These 
coefficients are determined through experimentation upon implementation of a new 
batch of TLD powder by the RPC.  The energy correction factor, KE is unity for proton 
beams. 
 
   
 
(           )
 Equation 6 
 
The linearity correction factor, KL is determined at the RPC by a linear function.  
Equation 7 is used by the RPC for the batch specific linearity correction factor, where m 
and b are batch specific coefficients.  These are also determined through 
experimentation upon implementation of a new batch of TLD powder. 
 
                   Equation 7 
 
The determination of the system sensitivity requires the use of standards which 
are irradiated to known doses using a 
60
Co machine. The system sensitivity is solved by 
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taking the irradiated dose of the standard TLD divided by fading correction, linearity 
correction and the average reading per milligram of the standard TLD powder. 
The use of TLD-100 has been validated for proton beams by experimentation 
and was demonstrated to have a standard deviation of less than ±4.0% [48].  This result 
is consistent with the expected ±5.0% uncertainty typically associated with 
thermoluminescent dosimetry. 
TLD measures physical dose while the TPS calculates biological dose.  The 
TLD physical dose was multiplied by the RBE of 1.1 for protons to yield the Cobalt 
centi-Gray Equivalent (CcGE).   
2.3.1.1 TLD Calibration 
By the method described above, the TLD calibration was performed starting 
with the irradiation of standards.  The standards were irradiated to 800 cGy by a 
60
Co 
machine, which was used because the dosimetry output on cobalt machines is very 
stable.  The characterization of the fading, linearity and energy correction coefficients 
has been performed previously by the RPC for the batch of TLD used, batch B11.  
Because the standards are of the same batch of TLD powder, their calibration was valid 
to use on the TLD irradiated in the phantom.  The fading, linearity and energy 
correction coefficients for this batch of TLD powder are tabulated in Table 2.1 and 
Table 2.2. 
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Coefficient Value 
a 1.2815 
b 0.00010885 
c 0.06781 
d 0.071908 
N 1.3493 
Table 2.1:  TLD correction coefficients used in Equation 6 for fading for batch B11 
Coefficient Value 
m -0.000335 
b 1.100495 
Table 2.2  TLD correction coefficients used in Equation 7 for linearity for batch 
B11 
2.3.2 Planar Dosimetry 
The planar dosimetry used in the phantom was GAFChromic® EBT2 film 
(International Specialty Products, Wayne, NJ) lot number: A03081203 with an 
expiration date of March 2014.  A diagram of this film is shown in Figure 2.6 [6].  The 
use of orthogonal films through the target allows for the reconstruction of isodose 
curves to compare with the original planned dose distribution.  These measured 2D 
planes can be compared to those in the original treatment plan to assess the accuracy of 
delivery by means of the gamma index [49]. 
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Figure 2.6:  Crossection of EBT2 film 
Another piece of film from the same batch as those in the tumor isocenter was 
used as a means of measuring the heart dose at its surface.  The heart is a critical 
structure in thoracic cases because it may be unintentionally irradiated distal to the 
target.  The film at the heart surface provides dosimetry for the heart.  From the planar 
dose distribution at the surface of the heart, the maximum heart dose will be measured 
and inferences on the DVH of the heart can be made.  Because the heart film was 
designed without a point dosimeter for normalization, the film was used as a qualitative 
tool to visually assess irradiated dose distributions.  Due to the low planned doses near 
the heart structure, the utilization of a calibration curve for the film may result in large 
uncertainties.   
In addition to providing an accurate means for 2D dosimetry, the active layer of 
EBT2 is approximately water equivalent in effective atomic number [10].  However, 
effective atomic number of the active layer does not equate to water equivalence for 
relative stopping power for the sheet of film.  Therefore, in proton measurements, EBT2 
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film has a relative stopping power approximately 8.0% higher than the Eclipse 
calibration curve as measured by the RPC.  At normal incidence to the beam, this 
discrepancy only corresponds to a range uncertainty of less than 0.03 mm.  With the 
film parallel to the beam, this uncertainty may become unacceptably large.  To avoid 
this effect, others have tilted film at angle no less than 5
o 
to the parallel beam axis [10].  
GafChromic EBT films have been shown to under respond in the Bragg peak region of 
proton beams [50] [51].  As the residual energy of a proton beam reduces below 
approximately 15 MeV, the magnitude of under response can reach as high as 20% [50] 
[51].  Because of this measured effect, measured doses in the distal region of the beams 
are expected to be lower than the TPS calculated doses. 
2.3.2.1 Film Calibration 
In order to determine a dose from the optical density of a film, the film must 
undergo a calibration to determine an empirical function for optical density vs. dose.  
The calibration was performed at the PTC-H by PTC-H staff.  Sections of a piece of 
film were irradiated to physical doses ranging between 45 cGy to 636 cGy at a depth  
located at the center of a 160 MeV passive scattered SOBP in a 10 cm x 10 cm field 
under solid water.  The optical density of each section of the calibration film was read 
three times by a CCD Microdensitometer for Radiochromic Film Model CCD100 
(Photoelectron Corporation, Lexington, MA) to provide an accurate average OD for 
each dose level.  As a result, the dose as a function of optical density was determined to 
be of the form of a third order polynomial in Equation 8 fit to the curve illustrated in 
Figure 2.7. 
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D = -8.9981(OD)
3
 + 29.72(OD)
2
 - 3.1581(OD) Equation 8 
 
Figure 2.7:  Film calibration curve and equation of fit for EBT2 lot #A03081203 in 
a clinical proton beam 
2.4 Imaging Acquisitions 
As mentioned in section 1.5.7, a 4DCT imaging acquisition is the preferred 
imaging acquisition for a thoracic tumor for proton therapy planning.  In addition to a 
free breathing 4DCT, a breath hold CT was also taken of the phantom.  Images for the 
breath hold treatment and the 2.13 cm amplitude spot scanned treatment were acquired 
by a Discovery ST PET/CT (General Electric HealthCare, Waukesha, WI).  Images for 
the 1.5 cm amplitude free breathing treatments were acquired by a LightSpeed RT 16 
CT (General Electric HealthCare, Waukesha, WI).    Proton treatment planning was 
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performed on the 4DCT image sets and is discussed in sections 2.5.1 and 2.5.2.  An 
image of the simulation setup is shown in Figure 2.8 below.   
 
Figure 2.8:  Phantom assembly setup for imaging acquisition 
2.4.1 4DCT 
The phantom was placed on the treatment couch and assembled.  Plastic 
fiducials were placed at the location of the localization lasers used by the radiation 
oncology department for patient localization on treatment machines.  The motion insert 
controlling device was set to repeat the free breathing motion profile indefinitely.   
Two 4DCT acquisitions were taken of the phantom in a free breathing 
simulation state which had 2.13 cm amplitude and 1.5 cm amplitude.  The scans 
consisted of a scout scan and imaging acquisitions at each axial slice position for a 
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duration of 7 seconds.  The 7 second cine duration allows for 1 second added to the 
approximate respiratory cycle of 6 seconds for the free breathing motion profile. 
The 4DCT acquisitions consisted of 2880 images which were binned by 
respiratory phase.  The respiratory phases were acquired by the RPM system by placing 
the reflective box on the adapter platform designed for the electromechanical cylinder.  
Traditional binning generated some noticeable artifacts on the periphery of the phantom 
thus a modification of the phasing bins was performed which allowed for the peaks of 
inspiration and expiration to be better matched with their respective phase bins.  The 
modified binning generated a 4DCT data sets which had fewer visual artifacts.  A 
maximum intensity projection (MIP) and average CT set were generated for both the 
traditionally binned and modified binned 4DCT data sets. 
2.4.1.1 Maximum Intensity Projection 
From the acquired 4DCT data set, a 3D MIP was generated.  A MIP contains the 
maximum voxel intensity from the ten phased image sets.  The MIP is particularly 
useful for visualizing and measuring the extent of tumor motion within a low HU 
material such as lung tissue.  Figure 2.9 is a sagittal image of the MIP mid-tumor. 
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Figure 2.9: MIP of the phantom in free breathing state, sagittal plane 
2.4.1.2 Average CT 
In a similar way to the MIP, the average CT is a 3D image set which consists of 
the average HU value over the ten respiratory phases acquired in the 4DCT.  Figure 
2.10 is a sagittal image of the average CT and is taken in the same plane as Figure 2.9 
above for comparison. 
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Figure 2.10:  Average CT of the phantom in free breathing state, sagittal plane 
2.4.2 Breath Hold CT 
The breath hold CT was taken by setting the electromechanical cylinder to the 
breath hold motion pattern.  The couch position was left unchanged from the reference 
alignment from the free breathing acquisition.  Three CT acquisitions were taken to 
assess the repeatability of the breath hold imaging.  All three scans were visually 
indistinguishable and deemed to have been acquired appropriately for a breath hold 
treatment plan.  An image of the mid-tumor sagittal plan is shown in Figure 2.11 and 
can be compared to Figure 2.9 and Figure 2.10 which include motion during the 
acquisition. 
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Figure 2.11:  Breath hold CT of the phantom, sagittal plane 
2.5 Treatment Planning 
Due to the phantom design, the treatment planning must be artificially restricted 
to avoid clinically unrealistic beam geometries.  The phantom lacks a contralateral lung 
and requires a tilted stand, which is placed on the treatment couch.  Thus, beam 
geometries resulting in irradiation from the contralateral side or the posterior side were 
avoided.  In general, the beam angles should be limited between anterior and left lateral 
fields. 
Four treatment plans were generated.  One plan was a passive scattered plan 
which utilized respiratory gating on Gantry 1 at the PTC-H.  The second plan was a 
scanning beam plan for delivery on Gantry 3 at the PTC-H which included 2.13 cm of 
target motion in amplitude.  The third plan was passive scattered plan which did not 
utilize respiratory gating on Gantry 1 at the PTC-H which included 1.5 cm amplitude.  
The fourth plan was a scanning beam plan for delivery on Gantry 3 at the PTC-H which 
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included 1.5 cm of target motion in amplitude.  The four plans mentioned above are 
representative of both passive scattered treatment techniques and spot scanned treatment 
techniques used currently in the radiation oncology field.  An appropriately delivered 
scattered breath hold treatment effectively yields a static irradiation state.  Therefore, 
the influence of motion amplitude can be assessed as well as the influence of the 
interplay effect between passive scattered treatments and spot scanned treatments.  
Each treatment plan was set to a single fraction with a prescribed dose of 600 
CcGE.  Clinically, this fractionation scheme is unreasonable, but is convenient to 
deliver with a single fraction to the phantom.  The prescribed dose of 600 CcGE is a 
dose level that yields better statistical results from the TLD and film dosimeters than the 
conventional 200 CcGE dose per fraction typical of clinical treatment plans.  To 
translate these treatment plans to clinically applicable plans, doses may be multiplied by 
ten to result in a 60 CcGE prescription, which is reasonable for proton therapy patients.  
2.5.1 Passive Scattered Breath Hold Treatment Plan 
A plan was generated for treatment of the target by a passive scattered beam 
under breath hold respiratory gating.  The prescribed dose was 600 CcGE and included 
two beams, an AP and a left lateral beam.  Additional beam parameters are listed in 
Table 2.3.  Proximal, distal and lateral clinical margins were used to achieve adequate 
tumor coverage utilizing the conventions currently employed by the PTC-H dosimetry 
team.  The dose prescription was normalized to 100% of the PTV volume receiving 600 
CcGE. 
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Passive Scattered Beam Treatment Plan Parameters 
Prescription: 600 CcGE 
Beam AP Lt Lat 
Gantry Angle [°] 0 90 
Couch Angle [°] 0 0 
Energy [MeV] 140 140 
SAD [cm] 270 270 
SOBP Width [cm] 5 4 
Range Modulator Wheel RMW_13 RMW_13 
Range Shifter Thickness [cm] - 1.3 
Dose Rate [MU/min] 100 100 
Snout Size [cm] 18 x 18 18 x 18 
Field Weight Factor 0.500 0.500 
MU 303.3 295.0 
Table 2.3:  Passive scattered breath hold treatment beam parameters 
Screen shots from the passive scattered breath hold treatment plan are shown in 
Figure 2.12 and Figure 2.13.  Figure 2.12 shows the surface dose at the location of the 
heart film.  Figure 2.14 shows the DVH of the passive scattered breath hold treatment 
plan.  The PTV receives an appropriate prescription dose while the ipsilateral lung and 
heart receive appropriately low doses.   
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Figure 2.12:  Resultant heart surface dose from passive scattered treatment plan 
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Figure 2.13:  Axial isodose plot of the target for the passive scattered breath hold 
treatment plan on the left and resultant isodose plot after manual HU adjustment 
of the target on the right 
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Figure 2.14:  DVH of the passive scattered treatment plan showing the PTV, 
healthy lung and heart 
2.5.1.1 MU Calculation of Scattered Plan 
The PCT-H follows a published formalism for MU calculations for passive 
scattered treatment plans [52].  To make the calculation process more time efficient, 
dose-to-MU measurements in water have been previously performed being modified by 
factors which estimate the dose and MU for a patient plan.  The patient plan was copied 
into the water phantom CT data set.  Because the geometry and beam parameters were 
copied, the dose at isocenter in the water phantom needs only be modified by the ROF, 
SOBPF and RSF to arrive at the dose at isocenter in the phantom plan.  The MU is thus 
calculated by Equation 9.  Where D is the physical dose measured in water by the TPS. 
   
 
             
 
Equation 9 
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2.5.1.2 Replanning for Manual Override of Target HU 
The target in the passive scattered breath hold plan was manually adjusted such 
that the target HU was set to 80 HU.  Region of interest measurements showed that the 
target had an average HU of approximately -40 HU.  Based on the stopping power 
measurements which have been done on high impact polystyrene, a material that 
behaved similar to the Eclipse calibration curve at the RLSP of high impact polystyrene 
should have an HU of 80.  The beams, blocks, and compensators were copied into the 
new modified CT image set and a 3D dose distribution was calculated with the beam 
characteristics left unchanged between plans.  Figure 2.13 above shows the replanned 
and recalculated dose distribution of the manually adjusted target next to the original 
planned dose distribution. 
2.5.2 Scanning Beam with 2.13 cm Breathing Amplitude Treatment Plan 
The scanned beam plan with 2.13 cm breathing amplitude was generated in 
Eclipse TPS using the MIP as a guide to determine the ITV and using the average CT as 
the image set to plan on.  The pencil beam gantry at PCT-H does not have motion 
monitoring equipment, therefore the free breathing imaging was used for the treatment 
plan.  Similar to the passive scattered plan, the scanned plan utilized the same OAR 
criteria as well as the same PTV coverage criteria and prescribed dose.  Table 2.4 shows 
a number of the plan parameters used in the scanned beam plan.  The plan utilized 
single field optimization. 
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Figure 2.15 shows a screen shot of an axial slice of the scanned beam treatment 
plan.  Figure 2.16 shows the DVH of the scanned beam treatment plan.  The PTV 
receives adequate prescription coverage, but contains hot spots resulting in a maximum 
dose of approximately 8 CGE.  The ipsilateral lung and the heart receive appropriately 
low doses.   
Scanned Beam Treatment Plan Parameters 
Prescription: 600 CcGE 
Beam AP Lt Lat 
Gantry Angle [°] 0 90 
Couch Angle [°] 0 0 
Energy [MeV] 118.6 108.0 
SAD [cm] 270 270 
SOBP Width [cm] 4.95 4.10 
Energy Absorber - - 
Dose Rate [MU/min] 100 100 
Maximum Field Size [cm] 30 x 30 30 x 30 
Field Weight Factor 0.500 0.500 
MU 154.62 173.85 
Table 2.4:  Scanned beam with 2.13 cm breathing amplitude treatment beam 
parameters 
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Figure 2.15:  Axial isodose plot of scanned beam with 2.13 cm breathing amplitude 
treatment plan on the left and resultant isodose plot after manual HU adjustment 
of the target on the right 
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Figure 2.16:  DVH of scanned beam treatment plan with PTV, healthy lung, and 
heart 
2.5.2.1 Dose Verification 
The dose delivery was verified by the patient specific techniques used by the 
PTC-H for the spot scanned beam.  The beam information from the treatment plan was 
exported to a cube of water and the dose was recalculated based on both beams entering 
with a gantry angle of 0º.  At three depths within the water phantom the two-
dimensional isodose plots were made on the central axis for each beam.  A two-
dimensional ionization chamber array called the MatriXX (IBA, Schwarzenbruck, 
Germany) was used with the corresponding depths of water equivalent buildup, to 
measure two-dimensional dose for each beam.  The two-dimensional measured and 
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calculated doses were analyzed by the gamma index with a minimum acceptance of 3% 
/ 3 mm 90% pass. 
2.5.2.2 Replanning for Manual Override of Target HU 
The target in the spot scanned plan was manually adjusted differently than that 
of the passive scattered breath hold plan.  The region of the target that was the highest 
intensity was assigned an HU of 80, while a surrounding region which in the average 
image was blurred between target and lung material was set to an HU of -100.  The 
beams were copied into the new modified CT image set and a 3D dose distribution was 
calculated with the beam characteristics left unchanged between plans.  Figure 2.15 
above shows the replanned and recalculated dose distribution of the manually adjusted 
target next to the original planned dose distribution. 
2.5.3 Passive Scattered Beam with 1.5 cm Breathing Amplitude Treatment Plan 
The scattered beam plan under free breathing motion of 1.5 cm in amplitude was 
generated in Eclipse TPS.  Target contouring was performed on the MIP and dose 
calculations were done on the average CT image set, similarly to the other free 
breathing treatment plans.  Table 2.5 shows a number of the plan parameters used in the 
passive scattered free breathing treatment plan.  The contoured plan was generated in 
the same way as described in section 2.5.2.2 above. 
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Scattered Beam Free Breathing Treatment Plan Parameters 
Prescription: 600 CcGE 
Beam AP Lt Lat 
Gantry Angle [°] 0 90 
Couch Angle [°] 0 0 
Energy [MeV] 160 140 
SAD [cm] 270 270 
SOBP Width [cm] 5 4 
Range Modulator RM_20 RM_21 
Range Shifter Thickness [cm] 2.7 1.5 
Dose Rate [MU/min] 100 100 
Snout Size [cm] 18 x 18 18 x 18 
Field Weight Factor 0.500 0.500 
MU 262.9 272.6 
Table 2.5: Passive scattered free breathing treatment beam parameters 
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Figure 2.17: Axial isodose plot of passive scanned free breathing treatment with 
1.5 cm amplitude on the left and resultant isodose plot after manual HU 
adjustment of the target on the right 
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Figure 2.18: DVH of the passive scattered free breathing treatment plan with 1.5 
cm amplitude motion 
 
2.5.4 Scanning Beam with 1.5 cm Breathing Amplitude Treatment Plan 
The scanned beam plan with 1.5 cm breathing amplitude was generated in 
Eclipse TPS identically to the previous scanning beam plan.  Table 2.6 shows a number 
of the plan parameters used in the scanned beam plan.  The plan utilized multi-field 
optimization. 
 
 
 
PTV 
Lung 
Heart 
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Scanned Beam Treatment Plan Parameters 
Prescription: 600 CcGE 
Beam AP Lt Lat 
Gantry Angle [°] 0 90 
Couch Angle [°] 0 0 
Energy [MeV] 121.2 109.4 
SAD [cm] 270 270 
SOBP Width [cm] 5.35 4.62 
Energy Absorber - - 
Dose Rate [MU/min] 100 100 
Field Size [cm] 25 x 25 25 x 25 
Field Weight Factor 0.500 0.500 
MU 128.99 144.45 
Table 2.6:  Scanned beam with 1.5 cm breathing amplitude treatment beam 
parameters 
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Figure 2.19: Axial isodose plot of scanned beam with 1.5 cm breathing amplitude 
treatment plan on the left and resultant isodose plot after manual HU adjustment 
of the target on the right 
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Figure 2.20: DVH of the spot scanned beam treatment plan with 1.5 cm breathing 
amplitude motion 
2.5.4.1 Dose Verification 
Point dose measurements were made with a PTW TN23343 Markus chamber 
(PTW, Freiburg, Germany) in both the AP and left lateral beams at the WET depth and 
off axis location of the TLD, which were 7.5 cm and 2 mm respectively.  Both beam 
parameters were copied into a solid water phantom image set used by the PTC-H for 
QA measurements.  Typically in QA measurements, both beams would be treated at the 
same gantry angle, however, the AP QA measured was done at 0˚ and the left lateral 
QA measurement was done at 90˚ to avoid uncertainty from gantry angle dependence.      
2.6 Treatment Delivery 
All treatments were delivered at the PTC-H and consisted of alignment to gantry 
lasers and irradiation of the two fields.  Following the full treatment delivery, the insert 
was removed from the phantom.  The irradiated film and TLD were removed and 
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replaced with unused film and TLD.  The treatment plan was delivered three times 
without moving the phantom shell on the treatment couch.      
2.6.1 Passive Scattered Breath Hold Plan 
The scattered beam was delivered with the use of the RPM system to deliver a 
breath hold treatment.  The phantom was aligned with the lasers to the fiducial markers.  
The phantom was then shifted to align to the target isocenter.  The shift to isocenter 
required was 4 mm to the patient left, 3.3 cm down and 9 mm into the gantry.  The 
RPM reflective box was set within view of the CCD camera.  The lead screw motor was 
set to repeat the breath hold pattern.  Treatment began with the AP beam and was 
paused when the insert went out of the breath hold phase of the breathing cycle.  Once 
the AP beam was delivered, the Lateral field was delivered in the same way.   
2.6.2 Spot Scanning Beam with 2.13 cm Breathing Amplitude Plan 
The phantom was aligned on the treatment couch with respect to the laser 
alignment and the three fiducial markers.  Isocenter was determined to be shifted from 
the surface fiducials by 4 mm to the patient left, 3 cm down and 1.9 cm into the gantry.  
The treatment couch was moved to align the planned isocenter with the gantry 
isocenter.  The phantom was then imaged with an AP and a lateral x-ray image.  The 
images were then compared to the DRRs generated in the TPS.  Because of the ridged 
landmarks such as the ribs, the image guided shift was found to be only necessary in 
one direction, a 2 mm shift in the superior direction.  Prior to irradiation, the free 
breathing motion file was run with an indefinite loop.  The patient plan was run in 
treatment mode with audio and visual verification that the motion insert remained in 
motion during the entirety of the treatment delivery.   
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2.6.3 Passive Scattered Free Breathing Plan 
The phantom was aligned with the lasers to the fiducial markers.  To align 
isocenter to the target, the couch was shifted 7 mm to patient left, 2.9 cm down and 2.1 
cm into the gantry.  Figure 2.21 below shows the treatment setup for this treatment plan. 
 
Figure 2.21: Image of the left lateral beam geometry for the passive scattered free 
breathing treatment 
2.6.4 Spot Scanned Beam with 1.5 cm Breathing Amplitude Plan 
The phantom was aligned on the couch with the lasers to the fiducial markers.  
Isocenter shifts were identical to the passive scattered free breathing plan mentioned 
above because the target and structure contours are identical.   
2.7 Measured vs Planned Dose Analysis 
After the film and TLD were measured, the measured dose was compared with the 
planned dose by the following method.  Film and TLD corrected doses were registered 
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using an established MATLAB software, RPCFilm.  Each piece of film contains pin 
pricks with known spacing to identify the orientation of the film with respect to the 
planned CT data set.  In this way, the film was registered to the 3D plan with a 3D dose 
distribution.  Therefore, the film was correctly registered to the reconstructed dose 
along the measured plane.   
Following registration a 2D gamma analysis was performed on each film plane, 
excluding the pin pricks as well as slits used to create the orthogonal film geometry.  
Since the phantom has not been studied previously, a baseline pixel passing percentage 
had not been established.  Two dose profiles were taken across each piece of film and 
were plotted with the TPS calculated dose profile along the same lines.  Within each 
treatment plan, the profiles were averaged and analyzed for repeatability.   
3 Results and Discussion 
3.1 Bone Equivalent Material Testing 
Of the nine materials tested for bone equivalency, the stopping power ratios for 
two types of clay were sufficiently close enough to the Eclipse calculated stopping 
power vs. HU calibration curve as well as within an appropriate HU range for bony 
anatomy.  These two clay materials are labeled material 2 and material 3 in Figure 3.1.  
The reproducibility of HU and relative stopping power were assessed for these two 
materials by making new samples from different batches of the same type of clay. 
The results of the second batch along with the results from the first batch are 
shown in Figure 3.2 where material 2.1 and 3.1 are the second batch results for material 
2 and material 3, respectively.  While the original material 2 measurement was identical 
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to the Eclipse calibration curve, the second batch was significantly different in both HU 
and relative stopping power.  The reproducibility of material 3 in relative stopping 
power was precise as well as accurate to 0.9% of the calibration curve at the average 
HU of the two measurements with σHU of 1.4% and σRLSP of 0.7%. 
The bone equivalent material that was chosen conforms well to RPC established 
baseline criteria for adequate phantom use in proton therapy, which is to be within ±5% 
agreement of the Eclipse calculated stopping power vs. HU calibration curve.  As 
determined with the bone material testing, a couple of acceptable proton equivalent 
phantom materials were found.  While the ±5% criteria was met, it was also equally 
important that the material be reproducible in case it had to be used for repairs or 
additional new phantoms.  The average RLSP agreement of material batches 2 and 2.1 
to the calibration curve was 1.4%, yet they demonstrate very poor reproducibility as 
seen in Figure 3.2 as compared to material batches 3 and 3.1. 
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Figure 3.1:  HU and relative stopping power of the materials tested for bone 
equivalency 
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Figure 3.2:  HU and relative stopping power reproducibility results of the two best 
proton bone substitutes 
3.2 Phantom Design and Dimensions 
The proton lung phantom was designed with the considerations stated in section 
2.1.1.  The drawings were used in the fabrication of the phantom.  Design components 
such as the ribs, dosimetry insert, and heart structure can be visualized in a sagittal 
transparent cross section in Figure 3.3. Figure 3.4 is a sagittal transparent cross section 
with dimensions in inches. Figure 3.5 and Figure 3.6 show the superior and inferior 
ends of the phantom respectively.  In these figures, the location of the heart film plane 
can be seen as the interface between the heart structure and the lung material.  
Additionally, these figures show the anthropomorphic design of the anterior portion of 
the phantom which increases in dimension towards the inferior end of the phantom.  
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Full technical drawings of the phantom and stands are included in section 5.1 of the 
appendix.  Images of the phantom after fabrication are shown in Figure 3.7 and Figure 
3.8 with insert motion facilitated by an electromechanical cylinder and lead screw, 
respectively. 
 
Figure 3.3:  Sagittal diagram of the phantom and its materials 
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Figure 3.4:  Sagittal diagram of the phantom with dimensions 
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Figure 3.5:  Superior end of phantom with dimensions 
71 
 
 
Figure 3.6: Inferior end of phantom with dimensions 
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Figure 3.7:  Image of the phantom assembly with electromechanical cylinder based 
motion 
 
Figure 3.8:  Image of phantom assembly with lead screw based motion 
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3.2.1 Phantom Design Conformity to Eclipse Calibration Curve 
The phantom was designed with the intention that no targets or normal tissue 
structures would require manual override of Hounsfield Units to obtain the appropriate 
RLSP value.  Manual overrides of regions require more time to plan a treatment.  
Manual overrides also may be a source of error in the treatment plan and delivery, even 
more so in 4DCT acquisitions than in conventional CT acquisitions.  Prior to the 
construction of the phantom, an estimation of the water equivalent depth of the center of 
the tumor during full inhalation and full exhalation from the AP beam line as well as the 
left lateral tumor water equivalent depth were calculated to the center of the target.  All 
range estimations were based only on the proton equivalent materials in the beam path 
and the distance traveled within each material.  From the known uncertainty in the bone 
material stopping power, an estimation of the propagated range uncertainty was 
estimated for all cases. 
In the AP full inhalation case, the range difference was calculated to be 0.2 mm 
overshoot compared to the Eclipse calculation.  At full exhalation, the range difference 
was calculated to be less than 0.01 mm compared to the Eclipse calculation.  In the left 
lateral cases, the actual phantom WET was higher than the Eclipse calculated WET by 
approximately 0.9 mm and 0.8 mm for the rib-in-path and rib-out-of-path cases 
respectively, as shown in Figure 3.11 and Figure 3.12.  The range of uncertainty (2σ) of 
the actual WET included the Eclipse calculated value in the AP cases as shown in 
Figure 3.9 and Figure 3.10.  The left lateral beam cases were not inclusive of the 
Eclipse calculated value within the range of uncertainty. 
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The proton scanning beam at MD Anderson Cancer Center has a range adjustment 
step size of 0.1 g/cm
2
 [16].  This means that a systematic difference in the water of less 
than 0.5 mm results in the same spot delivery.  However, in a phantom with a high 
composition of low density material, such as balsa, the range adjustment step size 
would be larger than 1 mm in some cases.  In this case, the systematic difference 
between the phantom materials and the Eclipse calculation becomes on the order of 
rounding error.  As discussed in section 1.5.5, the Eclipse calculated range value also 
includes the uncertainty in the HU to RLSP calibration curve, which is represented in 
the Eclipse calculated error bars.   Figure 3.9 - Figure 3.12 have gridline units equal to 
the water equivalent range adjustment step size of the scanning beam at the MD 
Anderson proton therapy center to illustrate the difference between the actual and 
calculated WET in each case.  It is also important to note that the range uncertainty 
when using EBT film for proton therapy dosimetry is approximately 0.5 mm [50].  
Therefore, with all four of the hypothetical beam line cases in submillimeter agreement 
to the Eclipse calculated WET, the range difference of using the lung phantom tissue 
substitutes is within the range of uncertainty in the film dosimetry and adjustment step 
size.   
While this analysis indicates that individual pathlengths along sample beam paths 
show a low range uncertainty at the center of the target, the target itself perturbs the 
beam greater than the TPS calculates.  The combination of a material that over responds 
and one that under responds for example may yield agreement at one depth, while 
differing at other depths.  Maximization of material RLSP agreement to the TPS 
minimizes the effect of range uncertainties. 
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Figure 3.9:  AP Full inhalation WET in phantom with propagated uncertainty 
compared to Eclipse calculated 
 
Figure 3.10:  AP Full exhalation WET in phantom with propagated uncertainty 
compared to Eclipse calculated 
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Figure 3.11:  Left lateral WET in phantom through ribs with propagated 
uncertainty compared to Eclipse calculated 
 
Figure 3.12:  Left lateral WET in phantom in between ribs with propagated 
uncertainty compared to Eclipse calculated 
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3.3 Motion Profile 
Tumor motion was simulated using a sin
6
(x) type function.  Others have shown 
that such a function is accurate to simulate respiratory motion [30].  Figure 3.13 is an 
example of sin
6
(x) type breathing motion with an amplitude of 2.13 cm and period of 6 
seconds. 
 
Figure 3.13:  Example of a sin
6
 type breathing pattern with 6 second period 
The sin
6
(x) type breathing motion profile used to generate Figure 3.13 was used 
to generate the electromechanical cylinder motion instruction file.  The 
electromechanical cylinder motion trace pattern is shown in Figure 3.14.  The motion 
pattern did not exactly reproduce the sin
6
(x) type breathing profile; however, the motion 
was highly reproducible as well as similar to a clinically relevant breathing pattern.  
Sixteen points were taken along the sin
6
(x) function and assigned a position and a 
velocity.   The ordinate of the plot in the position trace is in units of pulses, which is the 
smallest unit of motion the electromechanical cylinder can produce.  For this 
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electromechanical cylinder, a pulse is equal to 0.0075 mm.  The peak of the position 
trace corresponds to position at maximum inspiration, which is 2.13 cm inferior to 
position of maximum exhalation.  Once the electromechanical cylinder was replaced by 
the lead screw motor, the motion profile was converted to the lead screw motor 
software VMX (Velmex, Inc., Bloomfield, NY).  The same displacement and velocity 
points were used to generate the free breathing file for the new motion system as can be 
seen in Figure 3.15.   
 
Figure 3.14  Example of a free-breathing electromechanical cylinder position trace 
with a 6 second period 
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Figure 3.15:  Motion profile generated for VMX motion platform identical to that 
of electromechanical cylinder 
From the sin
6
(x) type motion, a breath hold simulation was generated by simply 
increasing the delay between breath cycles.  Breath hold treatments are common in 
radiation oncology; however, in lung cancer cases the breath hold time is typically 
shorter than patients without cancer.  Figure 3.16 shows an example of a modified 
sin
6
(x) type function to simulate a breath hold treatment where the breath hold time is 
approximately 13 seconds. 
Figure 3.17 shows the electromechanical cylinder motion trace that was 
generated from the free breathing file, but incorporated a longer time at maximum 
inspiration.  The breath hold time is approximately 13 seconds.  The breath hold pattern 
can be set to repeat indefinitely, which is not clinically observed, but does allow for a 
simple implementation of breath hold simulation.  In addition to the previous two 
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motion types, patient acquired data from a 4DCT study could also be used to simulate 
an irregular breathing pattern. 
 
Figure 3.16:  Example of a sin
6
 type breath hold pattern with a 19 second period 
 
Figure 3.17  Example of a position trace of a breath hold pattern with a period of 
approximately 19 seconds 
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3.4 Passive Scattered Breath Hold Treatment Dosimetry Measurements 
3.4.1 MU Requirements 
The resultant MU required for the AP and Lateral beams in the passive scattered 
plan were calculated to be 303 MU and 295 MU, respectively.   
3.4.2 Point Dose Comparison 
The point dose in each trial was compared to the dose at the same point 
calculated by the TPS.  The measurements and calculations were analyzed by 
calculating the CV and the ratio of the measured to the calculated point doses. 
Individual trial TLD results are shown in Table 3.1.  Each trial contained two 
double-loaded TLD measurements that were averaged.  The CV for the TLD 
measurements between trials of the passive scattered breath hold treatment delivery was 
calculated to be 1.5% with an average RPC/institution ratio of 1.027 for the contoured 
planned TLD dose and 1.002 for the original planned TLD dose.  The CV of all of the 
TLD readings for all trials was 2.2%.  Measured TLD doses were higher than planned 
doses for all three trials.      
 Average Measured 
TLD  Dose [CcGE] 
Average Calculated 
Dose [CcGE] 
RPC/Institution 
Trial 1 630.9 603.6 1.045 
Trial 2 615.2 603.6 1.019 
Trial 3 613.4 603.6 1.016 
Table 3.1:  Passive scattered breath hold plan point dose comparison by trial using 
the contoured planned TLD dose 
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3.4.3 Planar Dose Distribution Comparison 
The passive scattered breath hold dose distribution measurements were analyzed 
against the original calculated treatment plan as well as against the treatment plan with a 
target that was contoured and its HU manually adjusted.  Table 3.2 shows the percent of 
pixels passing the ±5% / 5mm criteria of the original plan, while Table 3.3 shows the 
percent of pixels passing the same criteria when the target HU was adjusted.  The 
average improvement of the contoured plan was an 11.8% increase in the percentage of 
the pixels passing the criteria.  The greatest improvement was found in the axial planes 
which had a percentage point passing difference of 13.8%, 21.6% and 24.0% for trials 
1, 2 and 3, respectively.  Figure 3.18 is a boxplot comparison of the two plans.  The 
median of the contoured plan was calculated to be 10.1% increase in the percentage of 
the pixels passing than the original plan.   
Trial Film Plane Percent Passing 
 
Trial 1 
Sagittal 79.5% 
Coronal 74.4% 
Axial 81.6% 
 
Trial 2 
Sagittal 76.7% 
Coronal 70.0% 
Axial 66.8% 
Trial 3 Sagittal 75.30% 
Coronal 73.7% 
Axial 64.9% 
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Table 3.2:  Gamma index (±5%/5mm criteria) for each plane and trial for the 
passive scattered breath hold plan 
Trial Film Plane Percent Passing 
 
Trial 1 
Sagittal 80.4% 
Coronal 82.3% 
Axial 95.4% 
 
Trial 2 
Sagittal 81.3% 
Coronal 82.9% 
Axial 88.5% 
Trial 3 Sagittal 84.5% 
Coronal 84.8% 
Axial 89.0% 
Table 3.3: Gamma index (±5%/5mm criteria) for each plane and trial for the 
passive scattered breath hold contoured plan when the target HU was adjusted 
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Figure 3.18: Comparison of passing percentage distributions for the film planes in 
the passive scattered breath hold plan and the contoured plan when the target HU 
was adjusted 
3.4.4 Distance to Agreement 
The target RLSP difference from the TPS resulted in a notable discrepancy 
between the measured film dose profiles from the original planned dose profiles distal 
to the target.  After manual HU adjustment of the target, the measured and planned 
profiles resulted in a smaller distance to agreement in the region distal to the target.  
This effect is shown in Figure 3.19.  All three profiles agree well proximal to the target, 
entering from the positive distances labeled as patient left.  The divergence between the 
original plan and the two measured dose profiles, is due to the material RLSP properties 
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of the target material being different from the RLSP properties the TPS calculates.  
Axial films resulted in the highest improvement in gamma index pass percentages 
because the axial plane has both beams displaying the distal disagreement with the 
original planned dose.  Improvements due to contouring and adjusting the target HU 
only occur within the target region or distal to the target.  The lateral dose profiles 
across the target comparing the calculations and measurements exhibit similar 
penumbra discrepancies to the original plan, which can be seen in Figure 3.20 where the 
lateral penumbra of the two treatment plans are nearly identical.  The complete set of 
TPS calculated and measured dose profiles for the passive scattered breath hold 
treatment can be found in section 5.3.1 with distance to agreement measurements at the 
5 CcGE and 3 CcGE dose levels where applicable and greater than 1 mm.      
 
Figure 3.19:  Comparison of measured film, original plan, and contoured plan 
when the target HU was adjusted dose profile from right to left on axial film 
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Figure 3.20: Comparison of measured film, original plan, and contoured plan 
when the target HU was adjusted dose profiles from right to left on sagittal film 
3.5 Scanned Beam with 2.13 cm Breathing Amplitude Dosimetry Measurements 
3.5.1 Dose Verification 
The clinical dose verification quality assurance as described in section 2.5.2.1 
met the acceptable ±3% / 3 mm pass criteria for all depths within each beam.  Table 3.4 
shows the ±3% / 3 mm percent passing points for each depth and beam.  Ideally, plans 
should yield at least 90% passing points at ±2% / 2 mm, however, only beams that yield 
less than 90% passing points at ±3% / 3 mm are considered for either replanning or a 
modification of the treatment plan.   
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Verification Plan Results 
Field Depth (cm) Pass (%) 
AP 6.9 95.7 
7.4 90.2 
8.4 97.2 
Left Lat. 5.9 89.8 
6.9 98.8 
Table 3.4:  Verification plan results for the 2.13 cm breathing amplitude spot 
scanned treatment plan 
3.5.2 Point Dose Comparison 
The point dose comparison was made by comparing the measured TLD readings 
with the average calculated dose over the movement range of the TLD.  The average 
calculated dose of the TLD was determined to be 692.4 CcGE for the original plan and 
714.0 CcGE for the contoured plan. The measured averages for all three irradiations 
was 681.0 CcGE corresponding to a RPC to institution ratios of 0.954 and 0.984 for the 
contoured (target HU adjusted) and original plans, respectively.  The three trials 
resulted in a CV of 2.9%.  Individual TLD trial results for the contoured plan are shown 
in Table 3.5. The CV of all of the TLD readings for all trials was 4.3%.  This variance 
corresponds approximately to twice that of the passive scattered breath hold TLD.   
Measured TLD doses were lower than planned doses for all three trials.      
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 Average Measured 
TLD  Dose [CcGE] 
Average Calculated 
Dose [CcGE] 
RPC/Institution 
Trial 1 676.1 714.0 0.947 
Trial 2 697.4 714.0 0.938 
Trial 3 669.5 714.0 0.977 
Table 3.5:  Spot Scanned beam with 2.13 cm breathing amplitude contoured plan 
(target HU adjusted) point dose comparison by trial 
3.5.3 Planar Dose Distribution Comparison 
The average pixel passing percentages for the original plan was 65.6%.  For the 
contoured plan the average was 75.2%.  The contoured plan resulted in an average pixel 
passing percentage point difference of 9.6%.  Similarly to the passive scattered breath 
hold plan, the film plane of greatest improvement from contouring the target was the 
axial plan with percentage point differences of 14.4% and 13.3% for trials 1 and 3, 
respectively.  Table 3.6 shows the pass percentages of the planes in each trial for the 
original plan, while Table 3.7 shows the pass percentages of the planes in each trial for 
the contoured plan (target HU adjusted).  The axial film in trial 2 was omitted from 
analysis because it was not within the insert during irradiation.  Figure 3.21 shows a 
boxplot distribution of both the original and contoured plan (target HU adjusted) 
gamma indices.  While the contoured plan (target HU adjusted) yielded a tighter 
distribution of passing percentages, it did include an extreme outlier, which is shown as 
a red plus mark and is greater than -3σ from the median. 
Average pixel passing percentages in the 60% range are quite low in the 
experience of the RPC.  Reasons for low pixel passing percentages for the original plan 
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include target material RLSP discrepancy, the interplay effect, high dose gradients, as 
well as severe target motion amplitude for this treatment modality.  Upon adjusting the 
target HU, the regions of highest failure were in the secondary adjusted target region.  
Because the amplitude was the largest out of all of the plans delivered, the assumption 
of a single HU for the secondary target region included the widest uncertainty.  To 
visualize this disagreement, the reader is referred to Figure 3.22 where the red failure 
regions in the contoured plan correspond in both the sagittal and coronal planes to this 
blurred target region.  
Trial Film Plane Percent Passing 
 
Trial 1 
Sagittal 77.2% 
Coronal 58.0% 
Axial 66.5% 
 
Trial 2 
Sagittal 64.9% 
Coronal 46.9% 
Axial - 
Trial 3 Sagittal 73.8% 
Coronal 74.6% 
Axial 62.9% 
Table 3.6:  Gamma index (±5%/5mm) for each plane and trial for the spot scanned 
plan 
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Trial Film Plane Percent Passing 
 
Trial 1 
Sagittal 79.6% 
Coronal 72.0% 
Axial 80.9% 
 
Trial 2 
Sagittal 77.1% 
Coronal 57.6% 
Axial - 
Trial 3 Sagittal 76.8% 
Coronal 81.3% 
Axial 76.2% 
Table 3.7: Gamma index (±5%/5mm) for each plane and trial for the spot scanned 
contoured plan (target HU adjusted). 
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Figure 3.21:  Comparison of passing percentage distributions for the film planes in 
the spot scanned plan with 2.13 cm breathing amplitude and the contoured plan 
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Figure 3.22:  Trial 2 of spot scanned plan with 2.13 cm breathing amplitude when 
the target HU was adjusted adjustment gamma analyses 
 
3.5.4 Distance to Agreement 
The measured dose profiles for the spot scanned treatment with 2.13 cm 
breathing amplitude differed more between each other than for any of the other 
treatment types.  As an example, the top plot in Figure 3.23 demonstrates that the 
average film dose profile agrees with the planned dose profile everywhere within the 5 
mm distance to agreement criteria.  However, the lower plot in Figure 3.23 shows that 
the doses vary noticeably especially in the region 2 cm superior to the film center.  Film 
dose used in profile plots as well as gamma analysis was normalized by the TLD dose, 
and in the case of the spot scanned treatment with 2.13 cm amplitude, the TLD dose had 
the largest CV out of all of the treatment types.  Additionally, the film and TLD are 
influenced by the largest amplitude of motion studied and thus have a higher 
susceptibility of dose differences from the interplay effect.  The complete set of profiles 
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for the passive scattered breath hold treatment can be found in section 5.3.2 with 
distance to agreement measurements at the 5 CcGE and 3 CcGE dose levels where 
applicable and above 1 mm.      
 
Figure 3.23:  Coronal film profile average (above) and individual (below) 
compared to contoured (target HU adjusted) TPS calculations. 
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3.6 Passive Scattered Free Breathing Treatment Dosimetry Measurements 
3.6.1 MU Requirements 
The resultant MU required for the AP and Lateral beams in the passive scattered 
free breathing plan were calculated to be 263 MU and 273 MU, respectively.   
3.6.2 Point Dose Verification 
Individual trial TLD results are shown in Table 3.8.  Each trial contained two 
double-loaded TLD measurements averaged.  The CV for the TLD measurements 
between trials of the passive scattered breath hold treatment delivery was calculated to 
be 0.4% with an average RPC/institution ratio of 0.969 for the contoured planned TLD 
dose and 0.971 for the original planned TLD dose.  The CV of all of the TLD readings 
for all trials was 0.74%.  Measured TLD doses were lower than planned doses for all 
three trials.        
 Average Measured 
TLD  Dose [CcGE] 
Average Calculated 
Dose [CcGE] 
RPC/Institution 
Trial 1 607.3 628.4 0.966 
Trial 2 609.7 628.4 0.971 
Trial 3 610.4 628.4 0.970 
Table 3.8:  Passive scattered free breathing contoured (target HU adjusted) plan 
point dose comparison by trial 
3.6.3 Planar Dose Distribution Comparison 
The average pixel passing percentage for the original plan was 62.5%.  The 
average pixel passing percentage for the contoured plan (target HU adjusted) was 
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73.9%.  The percentage point difference between the contoured and the original 
averages was 11.4%. 
Similarly to the spot scanned plan with 2.13 cm amplitude, the passive scattered 
free breathing treatment yielded pixel pass percentages in the 60% range for the original 
plan and in the 70% range for the contoured plan (target HU adjusted).  Average pixel 
passing percentages for the breath hold and free breathing passive scattered contoured 
plans were 85.4% and 73.9%, respectively.  This difference demonstrates the effect of 
motion as well as the manual HU adjustment of the secondary target region.      
Trial Film Plane Percent Passing 
 
Trial 1 
Sagittal 64.0% 
Coronal 67.7% 
Axial 57.2% 
 
Trial 2 
Sagittal 58.6% 
Coronal 66.8% 
Axial 63.5% 
Trial 3 Sagittal 56.8% 
Coronal 65.8% 
Axial 62.1% 
Table 3.9:  Gamma index (±5%/5mm) for each plane and trial for the passive 
scattered free breathing plan 
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Trial Film Plane Percent Passing 
 
Trial 1 
Sagittal 75.5% 
Coronal 79.6% 
Axial 69.7% 
 
Trial 2 
Sagittal 70.0% 
Coronal 78.9% 
Axial 74.3% 
Trial 3 Sagittal 68.7% 
Coronal 76.8% 
Axial 71.4% 
Table 3.10:  Gamma index (±5%/5mm) for each plane and trial for the passive 
scattered free breathing contoured plan 
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Figure 3.24:  Comparison of passing percentage distributions for the film planes in 
the passive scattered free breathing plan and the contoured plan 
3.6.4 Distance to Agreement 
Of the dose profiles compared, distance to agreement measurements were 
generally below the 5 mm criteria parallel to the beam path after manual HU 
adjustment.  The greatest distance to agreements were found in profiles perpendicular to 
the beam path in the region of the lateral penumbra.  An example of this can be seen in 
Figure 3.25 where the film dose was lower than the planned dose in the penumbra 
region. 
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Figure 3.25:  Sagittal dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered free breathing treatment when the 
target HU was adjusted 
3.7 Scanned Beam with 1.5 cm Breathing Amplitude Treatment Dosimetry 
Measurements 
3.7.1 Dose Verification 
The TPS calculated doses at the measurement point for the AP field and the left 
lateral field were 335.8 CcGE and 297.0 CcGE, respectively.  AP and left lateral 
measured doses were 337.5 CcGE and 291.2 CcGE, respectively.  The AP and left 
lateral point dose verification measurements were 0.8% high and 1.7% low, 
respectively.  This agreement was within the maintained ±2%  output consistency for 
the proton delivery system.  Although the dose was verified within acceptable criteria, 
the TLD location was in a region of high dose gradient, over which a 2 mm shift to the 
left resulted in a 4% increase in the point dose.  Additionally, while the dose was 
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verified within a static water phantom, the high dose gradient along with the interplay 
effect may yield a wider range of TLD doses within the anthropomorphic phantom. 
3.7.2 Point Dose Verification 
Individual trial TLD results are shown in Table 3.11.  Each trial contained two 
double-loaded TLD measurements averaged.  The CV for the TLD measurements 
between trials of the spot scanned treatment with 1.5 cm amplitude was calculated to be 
1.4% with an average RPC/institution ratio of 0.935 for the contoured planned TLD 
dose and 0.913 for the original planned TLD dose.  The CV of all of the TLD readings 
for all trials was 3.4%.  Measured TLD doses were lower than planned doses for all 
three trials.  
Of all the treatment types, the spot scanned with 1.5 cm amplitude yielded the 
greatest measured TLD disagreement with both original TLD dose and contoured TLD 
dose.  Verification within a homogeneous medium showed that the TLD was located in 
a region of high dose gradient which can be visualized in dose profile plots through the 
TLD location.  All profiles of the contoured and original plans show a dip in measured 
film dose particularly on the left, inferior region of the target.  The dose profiles can be 
found in section 5.3.4.  Future irradiations of the phantom should be planned in such a 
way as to place lower dose gradients within the TLD if possible.          
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 Average Measured 
TLD  Dose [CcGE] 
Average Calculated 
Dose [CcGE] 
RPC/Institution 
Trial 1 567.0 603.0 0.940 
Trial 2 566.6 603.0 0.924 
Trial 3 557.4 603.0 0.940 
Table 3.11:  Spot scanned contoured plan with 1.5 cm breathing amplitude point 
dose comparison 
3.7.3 Planar Dose Distribution Comparison 
The average pixel passing percentage for the original plan was 60.1%.  The 
average pixel passing percentage for the contoured (target HU adjusted) plan was 
72.2%.  The percentage point difference between the contoured and the original 
averages was 12.1%. 
Trial Film Plane Percent Passing 
 
Trial 1 
Sagittal 54.8% 
Coronal 65.3% 
Axial 59.8% 
 
Trial 2 
Sagittal 61.1% 
Coronal 56.4% 
Axial 66.9% 
Trial 3 Sagittal 54.0% 
Coronal 62.6% 
Axial 60.2% 
101 
 
Table 3.12:  Gamma index (±5%/5mm) for each plane and trial for the spot 
scanned plan with 1.5 cm breathing amplitude 
 
Trial Film Plane Percent Passing 
 
Trial 1 
Sagittal 66.1% 
Coronal 77.4% 
Axial 74.8% 
 
Trial 2 
Sagittal 72.1% 
Coronal 69.1% 
Axial 79.7% 
Trial 3 Sagittal 65.3% 
Coronal 76.7% 
Axial 68.6% 
Table 3.13:  Gamma index (±5%/5mm) for each plane and trial for the spot 
scanned contoured (target HU adjusted) plan with 1.5 cm breathing amplitude 
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Figure 3.26:  Comparison of passing percentage distributions for the film planes in 
the spot scanned with 1.5 cm breathing amplitude plan and the contoured (target 
HU adjusted)  plan 
3.7.4 Distance to Agreement 
Due to the low doses as measured by the TLD in the area of the steep dose 
gradient, the distance to agreement between the measured and calculated dose profiles 
in the film planes increased.  An example of this can be seen in Figure 3.27.  The 
measured TLD dose was used to normalize the film dose distributions, and in this case, 
resulted in profiles that, other than a systematic shift, seem to fit the shape of the 
planned contoured dose profile well, but are shifted lower. 
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Figure 3.27:  Axial dose profiles comparing the planned TPS dose with the 
measured film dose for the scanned treatment with 1.5 cm breathing amplitude 
when the target HU was adjusted 
3.8 Heart Dosimetry 
The film plane located at the surface of the heart structure was used for qualitative 
assessment of proper irradiation geometry.  Figure 3.28 shows the qualitative planned 
dose distribution as well as the qualitative film dose distribution for visual inspection.  
Due to the lack of TLD at the location of the film, the absolute dose of the film was not 
normalized, however visual inspection of the planned and measured dose distributions 
can be used to assess inappropriate irradiation geometries.  The maximum dose 
measured on the heart film for all treatment types was approximately 200 CcGE on the 
scanned beam with 2.13 cm breathing amplitude.  This dose level corresponds to a 
region on the film calibration curve which incorporates the greatest measured deviation 
from the calibration curve.  Additionally, the peak dose on the heart film corresponds to 
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a small region of the film.  Much of the film was exposed to doses well below the 
minimum film calibration measurement, thus they were extrapolated.  The film and 
planned dose in Figure 3.28 both show a region of lower dose in the shape of the target 
and a region of higher dose surrounding the target, which is due to the target margins.  
An example of using this film plane to assess inappropriate irradiation could be the 
visualization of hot or cold spots not visualized on the treatment plan.  Future work for 
the phantom may include a point dosimeter within the heart structure directly adjacent 
to the film plane to normalize the heart film dose distribution.  
 
Figure 3.28: Planned dose distribution along the plane of the heart film (left) and 
measured dose distribution of the heart film (right) with CT overlays for the spot 
scanned treatment plan with 2.13 cm breathing amplitude 
3.9 Determination of Appropriate Gamma Analysis Criteria 
In implementing a QA phantom for the RPC, consideration is needed to determine 
the appropriate institution passing criteria.  Currently, the RPC photon lung phantom 
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uses a ±5% / 5 mm gamma index which is centered around a TLD measured to planned 
dose ratio of 0.97.  Such a criteria allows for the ±5% dose ratios to be 1.02 and 0.92.  
Figure 3.29 shows for the contoured (target HU adjusted) proton plans, the TLD dose 
ratios for the phantom studied did not follow the same trend as observed with photons.  
Figure 3.29 shows the effects of changing the target material properties where SS2cm, 
PSBH, SS1.5cm and PSFB are the spot scanned 2.13 cm amplitude, passive scattered 
breath hold, spot scanned 1.5 cm amplitude and passive scattered free breathing 
treatments, respectively, and the abbreviations followed by a “C” are the contoured 
treatments.  When the target HU was manually adjusted, the recalculated TLD to 
calculated dose ratios rose for the passive scattered breath hold and spot scanned 
treatment with 1.5 cm amplitude, lowered for the spot scanned treatment with 2.13 cm 
amplitude and remained constant for the passive scattered free breathing treatment.  
Because of the point dose changes that occur from changing the target properties, a 
target material that better agrees with the TPS calibration curve is recommended.  An 
accurately planned TLD dose will better normalize the film dose distributions to result 
in more accurate representation of the difference between the planned and delivered 
dose to the phantom.  Future irradiations may result in a better statistical understanding 
of appropriate passing TLD dose ratio criteria. 
Each treatment plan irradiated demonstrated an improvement in percentage of 
pixels passing the 5% / 5 mm criteria when the target was contoured.  Figure 3.30 
shows the effects of contoured plans pixel pass percentage over all film planes 
irradiated.  This finding, demonstrates the necessity of careful material choice when 
designing a phantom for use in proton therapy.  The distributions of percentage of 
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pixels passing the ±5% / 5 mm gamma criteria for each treatment plan type are shown 
in Figure 3.31.  The of the contoured plans (target HU adjusted), the breath hold 
treatment demonstrated the highest pass percentage distribution, the 1.5 cm breathing 
amplitude treatments demonstrated similar pass percentage distributions and the 2.13 
cm breathing amplitude treatment included an extreme outlier.      
 
Figure 3.29:  Measured to planned dose ratios for all original and contoured plans 
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Figure 3.30:  Comparison of passing percentage distributions for the film planes in 
all original plans and contoured (target HU adjusted) plans 
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Figure 3.31:  Comparison of pixel passing percentages of individual original and 
contoured (target HU adjusted) plans 
4 Conclusions 
The hypothesis that a dynamic heterogeneous anthropomorphic thorax phantom 
can be designed and built to evaluate the end-to-end proton therapy treatment 
procedures for lung cancer to assure agreement between the measured and calculated 
dose within ±5% / 5 mm with a reproducibility of ±2% was met.  The phantom was 
used in four end-to-end treatments, each of which demonstrated the ability to compare 
measured doses to planned doses.   
The phantom was successfully able to be utilized as an end-to-end QA tool 
simulating proton therapy of a lung tumor.  While the average CV of each individual 
treatment plan was calculated to be 1.5%, meeting the hypothesized requirement, the 
CV of TLD readings before averaging resulted in as much as 4.3% and 3.4% for the 
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spot scanned treatment with 2.13 cm amplitude and the spot scanned treatment with 1.5 
cm amplitude.  This indicates that the interplay effect may require institutions to 
carefully design treatment plans when attempting to accurately irradiate moving point 
dosimeters with spot scanned proton beams.   
The high impact polystyrene target clearly demonstrated itself insufficient as a 
target material within this phantom without manual adjustment of HU.  Unfortunately, 
manual HU adjustment introduces its own uncertainty, much of which is not easily 
quantified.  In the case of static irradiation, manual HU adjustment is has the potential 
to be an accurate method for yielding planned and measured agreement, assuming the 
target is contoured very well and the material HU and RLSP have been measured very 
accurately.  However, when the target is in motion, manual HU adjustment requires the 
acceptance of greater uncertainty by either adjusting the calibration curve, which affects 
all pixels within the adjusted range, or adjusting the HU of regions that contain both 
target material and balsa wood on the average image.  Thus, in order to use the phantom 
for its intended purpose, the target should be replaced with either solid water or blue 
water.   
The current lung phantom pass criteria used by the RPC was not met for any of the 
treatment types involving free breathing motion.  This indicates that either the RPC 
reduce pass criteria for this phantom, or ask institutions to attempt motion mitigation 
techniques such as breath hold, or other gating methods.   
The addition of accurate bone simulating material successfully demonstrated that 
an added heterogeneity can be properly treated by the PTC-H beam lines.  In the static 
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irradiation case of the breath hold treatment, the addition of rib simulants did not 
noticeably affect the ability to deliver the planned dose to the phantom.  No bands of 
inappropriate rib simulant perturbation were noticeable in any of the film planes.  The 
incorporation of the rib simulants will effectively assess a proton center’s ability to 
accurately treat through bony anatomy and may prove useful for the implementation of 
future range or TPS algorithm studies as an end-to-end QA tool.   
 
5 Appendix 
5.1 Phantom and Support Technical Drawings 
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Figure 5.1: Technical drawing of phantom assembly 
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Figure 5.2: Technical drawing of phantom 
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Figure 5.3: Technical drawing of phantom stand 
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Figure 5.4  Technical drawing of electromechanical cylinder stand 
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Figure 5.5: Technical drawing of the heart insert 
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5.2 Gamma Analysis 
5.2.1 Passive Scattered Breath Hold Plan 
 
(a) Sagittal 79.5% pass    (b) Axial 81.6% pass 
 
(c) Coronal 74.4% pass 
Figure 5.6: Trial 1 of passive scattered breath hold plan gamma analyses 
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(a) Sagittal 76.7% pass    (b) Axial 66.8% pass 
 
(c) Coronal 70.0% pass 
Figure 5.7: Trial 2 of passive scattered breath hold plan gamma analyses 
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(a) Sagittal 75.0% pass    (b) Axial 64.9% pass 
 
(c) Coronal 73.7% pass 
Figure 5.8: Trial 3 of passive scattered breath hold plan gamma analyses 
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(a) Sagittal 80.4% pass    (b) Axial 95.4% pass 
 
(c) Coronal 82.3% pass 
Figure 5.9: Trial 1 of passive scattered breath hold plan when the target HU was 
adjusted gamma analyses 
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(a) Sagittal 81.3% pass    (b) Axial 88.5% pass 
 
(c) Coronal 82.9% pass 
Figure 5.10: Trial 2 of passive scattered breath hold plan when the target HU was 
adjusted gamma analyses 
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(a) Sagittal 84.5% pass    (b) Axial 89.0% pass 
 
(c) Coronal 84.8% pass 
Figure 5.11: Trial 3 of passive scattered breath hold plan when the target HU was 
adjusted gamma analyses 
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5.2.2 Spot Scanned Plan with 2.13 cm Breathing Amplitude 
 
(a) Sagittal 77.2% pass    (b) Axial 66.5% pass 
 
(c) Coronal 58.0% pass 
Figure 5.12: Trial 1 of spot scanned plan with 2.13 cm breathing amplitude gamma 
analyses 
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(a) Sagittal 64.9% pass    (b) Coronal 46.9% pass 
Figure 5.13:  Trial 2 of spot scanned plan with 2.13 cm breathing amplitude 
gamma analyses 
124 
 
 
(a) Sagittal 73.8% pass    (b) Axial 62.9% pass 
  
(c) Coronal 74.6% pass 
Figure 5.14: Trial 3 of spot scanned plan with 2.13 cm breathing amplitude gamma 
analyses 
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(a) Sagittal 79.6% pass    (b) Axial 80.9% pass 
 
(c) Coronal 72.0% pass 
Figure 5.15:  Trial 1 of spot scanned plan with 2.13 cm breathing amplitude when 
the target HU was adjusted gamma analyses 
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(a) Sagittal 77.1% pass    (b) Coronal 57.6% pass 
Figure 5.16:  Trial 2 of spot scanned plan with 2.13 cm breathing amplitude when 
the target HU was adjusted adjustment gamma analyses 
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(a) Sagittal 76.8% pass    (b) Axial 76.2% pass 
 
(c) Coronal 81.3% pass 
Figure 5.17:  Trial 3 of spot scanned plan with 2.13 cm breathing amplitude when 
the target HU was adjusted gamma analyses 
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5.2.3 Passive Scattered Free Breathing Plan 
 
(a) Sagittal 64.0% pass    (b) Axial 57.2% pass 
 
(c) Coronal 67.7% pass 
Figure 5.18: Trial 1 of passive scattered free breathing plan gamma analyses 
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(a) Sagittal 58.6% pass    (b) Axial 63.5% pass 
 
(c) Coronal 66.8% pass 
Figure 5.19:  Trial 2 of passive scattered free breathing plan gamma analyses 
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(a) Sagittal 56.8% pass    (b) Axial 62.1% pass 
 
(c) Coronal 65.8% pass 
Figure 5.20: Trial 3 of passive scattered free breathing plan gamma analyses 
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(a) Sagittal 75.5% pass    (b) Axial 69.7% pass 
 
(c) Coronal 79.6% pass 
Figure 5.21: Trial 1 of passive scattered free breathing plan when the target HU 
was adjusted gamma analyses 
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(a) Sagittal 70.0% pass    (b) Axial 74.3% pass 
 
(c) Coronal 78.9% pass 
Figure 5.22: Trial 2 of passive scattered free breathing plan when the target HU 
was adjusted gamma analyses 
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(a) Sagittal 68.7% pass    (b) Axial 71.4% pass 
 
(c) Coronal 76.8% pass 
Figure 5.23:  Trial 3 of passive scattered free breathing plan when the target HU 
was adjusted gamma analyses 
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5.2.4 Spot Scanned Plan with 1.5 cm Breathing Amplitude 
 
(a) Sagittal 54.8% pass    (b) Axial 59.9% pass 
 
(c) Coronal 65.3% pass 
Figure 5.24: Trial 1 of spot scanning treatment plan with 1.5 cm breathing 
amplitude gamma analyses 
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(a) Sagittal 61.1% pass   (b) Axial 66.9% pass 
 
(c) Coronal 56.4% pass 
Figure 5.25: Trial 2 of spot scanning treatment plan with 1.5 cm breathing 
amplitude gamma analyses 
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(a) Sagittal 54.0% pass    (b) Axial 60.2% pass 
 
(c) Coronal 62.6% pass 
Figure 5.26: Trial 3 of spot scanning treatment plan with 1.5 cm breathing 
amplitude gamma analyses 
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(a) Sagittal 66.1% pass    (b) Axial 74.8% pass 
 
(c) Coronal 77.4% pass 
Figure 5.27:  Trial 1 of spot scanned plan with 1.5 cm breathing amplitude when 
the target HU was adjusted gamma analyses 
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(a) Sagittal 72.1% pass    (b) Axial 79.7% pass 
 
(c) Coronal 69.1% pass 
Figure 5.28:  Trial 2 of spot scanned plan with 1.5 cm breathing amplitude when 
the target HU was adjusted gamma analyses 
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(a) Sagittal 65.3% pass    (b) Axial 68.6% pass 
 
(c) Coronal 76.7% pass 
Figure 5.29:  Trial 3 of spot scanned plan with 1.5 cm breathing amplitude when 
the target HU was adjusted gamma analyses 
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5.3 Film Profiles 
5.3.1 Passive Scattered Breath Hold Plan 
 
 
Figure 5.30: Sagittal dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered breath hold treatment 
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Figure 5.31: Axial dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered breath hold treatment 
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Figure 5.32: Coronal dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered breath hold treatment 
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Figure 5.33: Sagittal dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered breath hold treatment when the 
target HU was adjusted  
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Figure 5.34: Axial dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered breath hold treatment when the 
target HU was adjusted 
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Figure 5.35: Coronal dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered breath hold treatment when the 
target HU was adjusted 
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5.3.2 Scanned with 2.13 cm Breathing Amplitude Plan 
 
Figure 5.36: Sagittal dose profiles comparing the planned TPS dose with the 
measured film dose for the scanned treatment with 2.13 cm breathing amplitude 
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Figure 5.37: Axial dose profiles comparing the planned TPS dose with the 
measured film dose for the scanned treatment with 2.13 cm breathing amplitude 
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Figure 5.38: Coronal dose profiles comparing the planned TPS dose with the 
measured film dose for the scanned treatment with 2.13 cm breathing amplitude 
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Figure 5.39:  Sagittal dose profiles comparing the planned TPS dose with the 
measured film dose for spot scanned treatment with 2.13 cm breathing amplitude 
when the target HU was adjusted 
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Figure 5.40:  Axial dose profiles comparing the planned TPS dose with the 
measured film dose for spot scanned treatment with 2.13 cm breathing amplitude 
when the target HU was adjusted 
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Figure 5.41:  Coronal dose profiles comparing the planned TPS dose with the 
measured film dose for spot scanned treatment with 2.13 cm breathing amplitude 
when the target HU was adjusted 
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5.3.3 Passive Scattered Free Breathing Plan 
 
Figure 5.42:  Sagittal dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered free breathing treatment 
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Figure 5.43:  Axial dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered free breathing treatment 
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Figure 5.44:  Coronal dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered free breathing treatment 
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Figure 5.45:  Sagittal dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered free breathing treatment when the 
target HU was adjusted 
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Figure 5.46:  Axial dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered free breathing treatment when the 
target HU was adjusted  
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Figure 5.47:  Coronal dose profiles comparing the planned TPS dose with the 
measured film dose for the passive scattered free breathing treatment when the 
target HU was adjusted 
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5.3.4 Scanned with 1.5 cm Breathing Amplitude Plan 
 
Figure 5.48: Sagittal dose profiles comparing the planned TPS dose with the 
measured film dose for the scanned treatment with 1.5 cm breathing amplitude 
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Figure 5.49: Axial dose profiles comparing the planned TPS dose with the 
measured film dose for the scanned treatment with 1.5 cm breathing amplitude 
160 
 
 
Figure 5.50: Coronal dose profiles comparing the planned TPS dose with the 
measured film dose for the scanned treatment with 1.5 cm breathing amplitude 
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Figure 5.51:  Sagittal dose profiles comparing the planned TPS dose with the 
measured film dose for the scanned treatment with 1.5 cm breathing amplitude 
when the target HU was adjusted 
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Figure 5.52:  Axial dose profiles comparing the planned TPS dose with the 
measured film dose for the scanned treatment with 1.5 cm breathing amplitude 
when the target HU was adjusted 
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Figure 5.53:  Coronal dose profiles comparing the planned TPS dose with the 
measured film dose for the scanned treatment with 1.5 cm breathing amplitude 
when the target HU was adjusted 
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